US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
CA2369292C
(en)
|
1999-04-09 |
2010-09-21 |
Kyowa Hakko Kogyo Co. Ltd. |
Method of modulating the activity of functional immune molecules
|
US6693176B1
(en)
*
|
1999-07-23 |
2004-02-17 |
University Of Massachusetts |
Antitumor antibodies, proteins, and uses thereof
|
AU2016204535C1
(en)
*
|
2000-04-12 |
2017-02-23 |
Laboratoire Français Du Fractionnement Et Des Biotechnologies |
Anti-D monoclonal antibodies
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
US7625756B2
(en)
|
2000-06-28 |
2009-12-01 |
GycoFi, Inc. |
Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
|
US8697394B2
(en)
|
2000-06-28 |
2014-04-15 |
Glycofi, Inc. |
Production of modified glycoproteins having multiple antennary structures
|
DE60114830T2
(de)
|
2000-06-28 |
2006-08-03 |
Glycofi, Inc. |
Verfahren zur herstellung modifizierter glycoproteine
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
US20060029604A1
(en)
*
|
2000-06-28 |
2006-02-09 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
|
US20060034828A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
|
US20060024304A1
(en)
*
|
2000-06-28 |
2006-02-02 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
|
US20060034830A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
|
US7598055B2
(en)
*
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
US7863020B2
(en)
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
US6946292B2
(en)
*
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
CA2785941C
(en)
*
|
2000-10-06 |
2017-01-10 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody composition-producing cell
|
US7981420B2
(en)
|
2000-12-22 |
2011-07-19 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. |
Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
|
US20050144670A1
(en)
*
|
2001-03-06 |
2005-06-30 |
Kazuhito Fujiyama |
Plant cell having animal-type sugar chain adding function
|
ATE430580T1
(de)
*
|
2001-10-25 |
2009-05-15 |
Genentech Inc |
Glycoprotein-zusammensetzungen
|
US7935338B2
(en)
*
|
2001-12-11 |
2011-05-03 |
University Of Massachusetts |
Antibodies to treat cancer
|
US20040093621A1
(en)
*
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
MXPA04006357A
(es)
|
2001-12-27 |
2005-03-31 |
Glycofi Inc |
Metodos para disenar estructuras de carbohidrato del tipo de mamifero.
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US6964784B2
(en)
*
|
2002-03-07 |
2005-11-15 |
Optigenex, Inc. |
Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
|
EP1500400A4
(en)
*
|
2002-04-09 |
2006-10-11 |
Kyowa Hakko Kogyo Kk |
MEDICAMENT CONTAINING ANTIBODY COMPOSITION
|
AU2003236015A1
(en)
*
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition
|
AU2003236018A1
(en)
*
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
MXPA04009924A
(es)
*
|
2002-04-09 |
2005-07-01 |
Kyowa Hakko Kogyo Kk |
Celulas de genoma modificado.
|
AU2003236020B2
(en)
|
2002-04-09 |
2009-03-19 |
Kyowa Hakko Kirin Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
|
EP1502603A4
(en)
*
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
|
WO2004022597A1
(ja)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3の血中可溶化n端ペプチドに対する抗体
|
FR2844455B1
(fr)
*
|
2002-09-13 |
2007-12-14 |
Lab Francais Du Fractionnement |
Traitement des pathologies echappant a la reponse immune par des anticorps optimises
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
US20040115204A1
(en)
*
|
2002-12-11 |
2004-06-17 |
Fanger Gary R. |
Antibodies to treat cancer
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US7332299B2
(en)
|
2003-02-20 |
2008-02-19 |
Glycofi, Inc. |
Endomannosidases in the modification of glycoproteins in eukaryotes
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
JP4739954B2
(ja)
|
2003-03-13 |
2011-08-03 |
中外製薬株式会社 |
変異受容体に対するアゴニスト活性を有するリガンド
|
US7790399B2
(en)
*
|
2003-04-03 |
2010-09-07 |
Laboratoire Francais du Fractionnement et des Biotechnolgies (LFB) |
Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
WO2005017155A1
(ja)
|
2003-06-18 |
2005-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
フコーストランスポーター
|
EP2204190A1
(en)
|
2003-07-15 |
2010-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
IgM production by transformed cells and methods for quantifying said IgM production
|
FR2858235B1
(fr)
*
|
2003-07-31 |
2006-02-17 |
Lab Francais Du Fractionnement |
Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
|
US20070142627A1
(en)
|
2003-08-01 |
2007-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Sugar-chain-altered anti-hm1.24 antibody
|
EP2311468B1
(en)
|
2003-08-08 |
2014-01-15 |
Perseus Proteomics Inc. |
Gene overexpressed in cancer
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
US20050287138A1
(en)
*
|
2003-10-08 |
2005-12-29 |
Kyowa Hakko Kogyo Co., Ltd. |
CCR4-specific antibody composition
|
US20050226867A1
(en)
*
|
2003-10-08 |
2005-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
IL-5R-specific antibody composition
|
JPWO2005035583A1
(ja)
*
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
Il−5受容体に特異的に結合する抗体組成物
|
JPWO2005035582A1
(ja)
*
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
Ccr4に特異的に結合する抗体組成物
|
WO2005035586A1
(ja)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
融合蛋白質組成物
|
US7691810B2
(en)
|
2003-10-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Method of producing recombinant antithrombin III composition
|
US20060021071A1
(en)
*
|
2003-10-09 |
2006-01-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Cell in which genome is modified
|
JP4762717B2
(ja)
|
2003-10-09 |
2011-08-31 |
中外製薬株式会社 |
IgM高濃度安定化溶液
|
AU2004280064A1
(en)
*
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Genomically modified cell neutralized to serum-free system
|
US20070134759A1
(en)
*
|
2003-10-09 |
2007-06-14 |
Harue Nishiya |
Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
|
JPWO2005035741A1
(ja)
*
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
ゲノムが改変された細胞
|
PL1692182T3
(pl)
|
2003-11-05 |
2010-09-30 |
Roche Glycart Ag |
Przeciwciała CD20 o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
|
EP2221315A1
(en)
|
2003-12-04 |
2010-08-25 |
Xencor, Inc. |
Methods of generating variant proteins with increased host string content and compositions thereof
|
JPWO2005053742A1
(ja)
*
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
EP2383295B1
(en)
|
2003-12-10 |
2015-03-11 |
E. R. Squibb & Sons, L.L.C. |
IP-10 antibodies and their uses
|
CA2546054C
(en)
|
2003-12-10 |
2014-05-13 |
Medarex, Inc. |
Interferon alpha antibodies and their uses
|
WO2005058244A2
(en)
*
|
2003-12-15 |
2005-06-30 |
Alexion Pharmaceuticals, Inc. |
Novel anti-dc-sign antibodies
|
WO2005063820A2
(en)
|
2003-12-30 |
2005-07-14 |
Merck Patent Gmbh |
Il-7 fusion proteins
|
JP2005224240A
(ja)
*
|
2004-01-13 |
2005-08-25 |
Kyowa Hakko Kogyo Co Ltd |
ノックアウト非ヒト動物から樹立された不死化細胞株
|
AU2005206277B2
(en)
*
|
2004-01-22 |
2011-06-23 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
JP4932699B2
(ja)
*
|
2004-03-17 |
2012-05-16 |
グライコフィ, インコーポレイテッド |
真菌および酵母におけるシチジンモノホスフェート−シアル酸合成経路を操作する方法
|
CA2561264A1
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
WO2005117978A2
(en)
|
2004-06-04 |
2005-12-15 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
EP1765400A2
(en)
*
|
2004-06-04 |
2007-03-28 |
Genentech, Inc. |
Method for treating lupus
|
PT2662390T
(pt)
|
2004-06-21 |
2017-10-09 |
Squibb & Sons Llc |
Anticorpos contra recetor 1 do interferão alfa e as suas utilizações
|
MY145073A
(en)
|
2004-07-09 |
2011-12-15 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican 3 antibody
|
EP1765871A1
(en)
|
2004-07-14 |
2007-03-28 |
Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG |
N-glycosylated antibody
|
JP2008505174A
(ja)
|
2004-07-15 |
2008-02-21 |
ゼンコー・インコーポレイテッド |
最適化Fc変異体
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
KR20130103580A
(ko)
|
2004-08-24 |
2013-09-23 |
추가이 세이야쿠 가부시키가이샤 |
항 글리피칸 3 항체를 이용한 어쥬번트 요법
|
EP1812060A2
(en)
|
2004-10-05 |
2007-08-01 |
Genentech, Inc. |
Method for treating vasculitis
|
MX2007004593A
(es)
*
|
2004-10-26 |
2007-06-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-glipican 3 que tiene cadena de azucar modificada.
|
WO2006053301A2
(en)
|
2004-11-12 |
2006-05-18 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
JPWO2006067847A1
(ja)
|
2004-12-22 |
2008-06-12 |
中外製薬株式会社 |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
DK1871805T3
(da)
|
2005-02-07 |
2019-12-02 |
Roche Glycart Ag |
Antigenbindende molekyler der binder egfr, vektorer der koder derfor, og anvendelser deraf
|
EP1853718B1
(en)
|
2005-02-15 |
2015-08-05 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
JP5249587B2
(ja)
*
|
2005-02-18 |
2013-07-31 |
メダレックス, インク. |
フコシル残基を欠く前立腺特異的膜抗原(psma)に対するモノクローナル抗体
|
IL322052A
(en)
|
2005-03-23 |
2025-09-01 |
Genmab As |
Antibodies against 38CD for the treatment of multiple myeloma
|
CA2604885A1
(en)
|
2005-04-07 |
2006-10-19 |
Guoying Yu |
Cacna1e in cancer diagnosis, detection and treatment
|
AU2006235258A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cancer-related genes
|
ES2971647T3
(es)
|
2005-04-15 |
2024-06-06 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
EP2221316A1
(en)
|
2005-05-05 |
2010-08-25 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
ATE460672T1
(de)
|
2005-05-20 |
2010-03-15 |
Genentech Inc |
Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
|
JP2008546805A
(ja)
|
2005-06-23 |
2008-12-25 |
メディミューン,エルエルシー |
最適な凝集および断片化プロフィールを有する抗体製剤
|
CN103145841A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
CA3201163A1
(en)
|
2005-07-01 |
2007-01-11 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
AU2006268227A1
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc |
Optimized anti-Ep-CAM antibodies
|
ES2579602T3
(es)
|
2005-08-10 |
2016-08-12 |
Macrogenics, Inc. |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
|
SG2014010029A
(en)
|
2005-08-19 |
2014-08-28 |
Abbott Lab |
Dual variable domain immunoglobin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500358A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070071745A1
(en)
|
2005-08-26 |
2007-03-29 |
Pablo Umana |
Modified antigen binding molecules with altered cell signaling activity
|
BRPI0616600A2
(pt)
*
|
2005-08-31 |
2011-06-28 |
Centocor Inc |
linhagens de célula hospedeira para produção de região constante de anticorpo com função efetora aumentada
|
US20090136525A1
(en)
*
|
2005-09-02 |
2009-05-28 |
Tillman Gerngross |
Immunoglobulins Comprising Predominantly a Glcnacman3Glcnac2 Glycoform
|
WO2007029054A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Glycofi, Inc. |
Immunoglobulin comprising predominantly a man7glcnac2, man8glcnac2 glycoform
|
JP2009510002A
(ja)
|
2005-09-30 |
2009-03-12 |
アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
JPWO2007046439A1
(ja)
|
2005-10-18 |
2009-04-23 |
独立行政法人農業生物資源研究所 |
抗体を産生するトランスジェニックカイコとその製造方法
|
US7910708B2
(en)
|
2005-10-21 |
2011-03-22 |
Novartis Ag |
Anti-IL13 human antibodies
|
PT1945665E
(pt)
|
2005-10-21 |
2012-04-20 |
Genzyme Corp |
Terapêuticas à base de anticorpos com atividade adcc reforçada
|
FR2892724B1
(fr)
*
|
2005-11-02 |
2008-01-04 |
Lab Francais Du Fractionnement |
Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
|
WO2007055916A2
(en)
*
|
2005-11-07 |
2007-05-18 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
WO2007062852A2
(en)
|
2005-11-30 |
2007-06-07 |
Abbott Laboratories |
ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES
|
HRP20140240T4
(hr)
|
2005-11-30 |
2017-02-24 |
Abbvie Inc. |
Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
|
KR101453570B1
(ko)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
|
EA017491B1
(ru)
|
2005-12-08 |
2012-12-28 |
Медарекс, Инк. |
Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител
|
BRPI0620795A2
(pt)
|
2005-12-30 |
2011-11-22 |
Merck Patent Ges Mit Beschronkter Haftung |
anticorpos anti-cd19 imunogenicidade reduzida
|
DK1966238T3
(da)
|
2005-12-30 |
2012-07-16 |
Merck Patent Gmbh |
INTERLEUKIN-12P40-varianter med forbedret stabilitet
|
DE602007008357D1
(de)
*
|
2006-01-04 |
2010-09-23 |
Novartis Ag |
Antikörperabhängiger zellulärer zytotoxizitätstest
|
AU2007248444B2
(en)
|
2006-01-05 |
2012-10-25 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
EP1974040B1
(en)
|
2006-01-17 |
2012-10-03 |
Biolex Therapeutics, Inc. |
Compositions and methods for humanization and optimization of N-glycans in plants
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
WO2008029276A2
(en)
|
2006-02-02 |
2008-03-13 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
EP2540741A1
(en)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
JP2009531031A
(ja)
|
2006-03-23 |
2009-09-03 |
ノバルティス アーゲー |
抗−腫瘍細胞抗原抗体療法
|
US20080014203A1
(en)
*
|
2006-04-11 |
2008-01-17 |
Silke Hansen |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
MX2008015132A
(es)
|
2006-05-30 |
2008-12-10 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
AR061246A1
(es)
|
2006-06-06 |
2008-08-13 |
Genentech Inc |
Anticuerpos anti- dill4 y metodos que los usan
|
CA2654304A1
(en)
*
|
2006-06-06 |
2007-12-13 |
Genentech, Inc. |
Compositions and methods for modulating vascular development
|
EP1878747A1
(en)
|
2006-07-11 |
2008-01-16 |
greenovation Biotech GmbH |
Glyco-engineered antibodies
|
ES2612383T3
(es)
|
2006-07-19 |
2017-05-16 |
The Trustees Of The University Of Pennsylvania |
WSX-1/IL-27 como una diana para respuestas antiinflamatorias
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
WO2008020586A1
(en)
|
2006-08-14 |
2008-02-21 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
|
ES2402591T3
(es)
|
2006-08-14 |
2013-05-07 |
Xencor Inc. |
Anticuerpos optimizados que seleccionan como diana CD19
|
EA200970250A1
(ru)
|
2006-09-05 |
2010-02-26 |
Медарекс, Инк. |
Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
|
ATE551071T1
(de)
*
|
2006-09-08 |
2012-04-15 |
Medimmune Llc |
Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
|
RU2472807C2
(ru)
|
2006-09-08 |
2013-01-20 |
Эбботт Лэборетриз |
Интерлейкин-13-связывающие белки
|
MX2009002388A
(es)
|
2006-09-10 |
2009-06-02 |
Glycotope Gmbh |
Uso de celulas humanas originarias de leucemia mieloide para la expresion de anticuerpos.
|
EP2064240A2
(en)
|
2006-09-18 |
2009-06-03 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
CA2665239A1
(en)
|
2006-10-02 |
2008-05-22 |
Medarex, Inc. |
Human antibodies that bind cxcr4 and uses thereof
|
BRPI0719202A2
(pt)
|
2006-10-12 |
2015-06-16 |
Forerunner Pharma Res Co Ltd |
Diagnóstico e tratamento de câncer usando anticorpo antiereg
|
UA94484C2
(uk)
|
2006-10-12 |
2011-05-10 |
Дженентек, Інк. |
Антитіла до лімфотоксину-альфа
|
US20100061933A1
(en)
|
2006-10-20 |
2010-03-11 |
Naoki Kimura |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
RU2483080C2
(ru)
|
2006-10-27 |
2013-05-27 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты и их применение
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
WO2008076560A2
(en)
|
2006-11-15 |
2008-06-26 |
Medarex, Inc. |
Human monoclonal antibodies to btla and methods of use
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
CN103172743B
(zh)
|
2006-12-01 |
2015-04-08 |
梅达雷克斯有限责任公司 |
结合cd22的人抗体及其用途
|
US20080127996A1
(en)
*
|
2006-12-04 |
2008-06-05 |
Weinhold Dennis G |
Method and apparatus to remediate an acid and/or liquid spill
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
EP2103628A4
(en)
|
2006-12-14 |
2012-02-22 |
Forerunner Pharma Res Co Ltd |
MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
|
CA2672468A1
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
US20110236374A1
(en)
|
2007-01-24 |
2011-09-29 |
Kyowa Hakko Kirin Co., Ltd. |
Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
|
CN101652389A
(zh)
|
2007-02-09 |
2010-02-17 |
健泰科生物技术公司 |
抗robo4抗体及其用途
|
EP2121745A2
(en)
|
2007-02-26 |
2009-11-25 |
Oxford Genome Sciences (UK) Limited |
Proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
KR20090130029A
(ko)
*
|
2007-03-07 |
2009-12-17 |
글리코파이, 인크. |
푸코실화가 변형된 당단백질의 제조
|
PT3199180T
(pt)
|
2007-03-08 |
2022-04-01 |
Univ Monash |
Anticorpos epha3 para o tratamento de tumores sólidos
|
WO2008137915A2
(en)
|
2007-05-07 |
2008-11-13 |
Medimmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
LT3072525T
(lt)
|
2007-05-14 |
2018-05-10 |
Astrazeneca Ab |
Bazofilų lygių mažinimo būdai
|
CA2693053C
(en)
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
PL2158221T3
(pl)
|
2007-06-21 |
2019-02-28 |
Macrogenics, Inc. |
Kowalencyjne diaciała i ich zastosowania
|
US8722858B2
(en)
|
2007-06-25 |
2014-05-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-Prominin-1 antibody having ADCC activity or CDC activity
|
CA2691734A1
(en)
*
|
2007-07-04 |
2009-01-08 |
Forerunner Pharma Research Co., Ltd. |
Anti-muc17 antibody
|
EP2626371A1
(en)
|
2007-07-31 |
2013-08-14 |
MedImmune, LLC |
Multispecific epitope binding proteins and uses thereof
|
ME00973B
(me)
*
|
2007-07-31 |
2012-06-20 |
Regeneron Pharma |
Humana antitjela prema humanom cd20 i postupak njihovog korišćenja
|
US8501907B2
(en)
|
2007-08-10 |
2013-08-06 |
Janssen Biotech, Inc. |
Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
|
SI2769729T1
(sl)
|
2007-09-04 |
2019-06-28 |
Compugen Ltd. |
Polipeptidin in polinukleotidi in njihove uporabe kot tarča zdravila za izdelavo zdravil in bioloških zdravil
|
RU2526512C2
(ru)
|
2007-09-26 |
2014-08-20 |
Чугаи Сейяку Кабусики Кайся |
Модифицированная константная область антитела
|
ES2637918T3
(es)
|
2007-09-28 |
2017-10-17 |
Janssen Biotech, Inc. |
Métodos y conformaciones estructurales de preparaciones de anticuerpos con aumento de la resistencia a las proteasas
|
RU2010116756A
(ru)
*
|
2007-09-28 |
2011-11-10 |
Чугаи Сейяку Кабусики Кайся (Jp) |
Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
ES2663077T3
(es)
|
2007-11-02 |
2018-04-11 |
Novartis Ag |
Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
|
KR20160129099A
(ko)
|
2007-11-07 |
2016-11-08 |
제넨테크, 인크. |
미생물 질환의 치료를 위한 조성물 및 방법
|
AU2008321840B2
(en)
|
2007-11-14 |
2014-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-GPR49 antibody
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
RU2563343C2
(ru)
|
2007-12-14 |
2015-09-20 |
Ново Нордиск А/С |
Антитела к человеческому nkg2d и их применения
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
ES2518415T3
(es)
|
2007-12-21 |
2014-11-05 |
Medimmune Limited |
Elementos de unión para receptor alfa de interleucina-4 (IL-4Ralfa)
|
BRPI0821604B1
(pt)
|
2007-12-26 |
2021-09-21 |
Xencor, Inc |
Polipeptídeo isolado compreendendo um fc variante de polipeptídeo de fc de igg humano, método para produzir o mesmo e uso de anticorpo
|
AU2009203464A1
(en)
|
2008-01-11 |
2009-07-16 |
Forerunner Pharma Research Co., Ltd. |
Anti-CLDN6 antibody
|
KR20100107501A
(ko)
|
2008-01-18 |
2010-10-05 |
메디뮨 엘엘씨 |
부위 특이적 접합을 위한 시스테인 조작 항체
|
US8039596B2
(en)
|
2008-02-05 |
2011-10-18 |
Bristol-Myers Squibb Company |
Alpha 5-beta 1 antibodies and their uses
|
KR101666229B1
(ko)
|
2008-02-08 |
2016-10-14 |
메디뮨 엘엘씨 |
Fc 리간드 친화성이 감소된 항-IFNAR1 항체
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
KR101614494B1
(ko)
|
2008-04-02 |
2016-04-22 |
마크로제닉스, 인크. |
Bcr-복합체-특이적 항체 및 그것의 사용 방법
|
MX2010010737A
(es)
|
2008-04-02 |
2010-12-20 |
Macrogenics Inc |
Anticuerpos especificos para her2/neu y metodos para utilizar los mismos.
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
TWI818604B
(zh)
|
2008-04-11 |
2023-10-11 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗原結合分子
|
JP5522405B2
(ja)
|
2008-04-25 |
2014-06-18 |
協和発酵キリン株式会社 |
安定な多価抗体
|
EP2899209A1
(en)
|
2008-04-29 |
2015-07-29 |
Abbvie Inc. |
Dual Variable Domain Immunoglobulins and uses thereof
|
EP2274331B1
(en)
|
2008-05-02 |
2013-11-06 |
Novartis AG |
Improved fibronectin-based binding molecules and uses thereof
|
AU2009245354C1
(en)
|
2008-05-09 |
2016-05-19 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
|
US9226934B2
(en)
|
2008-06-02 |
2016-01-05 |
The University Of Tokyo |
Anti-cancer drug
|
UY31861A
(es)
|
2008-06-03 |
2010-01-05 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
NZ589434A
(en)
|
2008-06-03 |
2012-11-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2010033279A2
(en)
|
2008-06-04 |
2010-03-25 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
US9023999B2
(en)
|
2008-06-30 |
2015-05-05 |
Kyowa Hakko Kirin Co., Ltd |
Anti-CD27 antibody
|
KR101054362B1
(ko)
*
|
2008-07-03 |
2011-08-05 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
JP2011527579A
(ja)
|
2008-07-08 |
2011-11-04 |
アボット・ラボラトリーズ |
プロスタグランジンe2結合タンパク質およびこの使用
|
CA2729949A1
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
CN102171570B
(zh)
|
2008-08-05 |
2014-10-15 |
东丽株式会社 |
用于检测癌的方法
|
PT2328616E
(pt)
|
2008-08-05 |
2015-08-26 |
Novartis Ag |
Composições e métodos para anticorpos dirigidos à proteína c5 do complemento
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
WO2010018846A1
(ja)
*
|
2008-08-13 |
2010-02-18 |
協和発酵キリン株式会社 |
ガングリオシドgm2に特異的に結合する抗体組成物を含む医薬
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
DK2853545T3
(en)
|
2008-09-17 |
2016-08-29 |
Xencor Inc |
Antibody specific for IgE
|
AU2009294415B2
(en)
|
2008-09-19 |
2015-09-24 |
Medimmune Llc |
Antibodies directed to DLL4 and uses thereof
|
EP2340305A1
(en)
|
2008-09-26 |
2011-07-06 |
Eureka Therapeutics, Inc. |
Cell lines and proteins with variant glycosylation pattern
|
CN104447990B
(zh)
|
2008-10-14 |
2019-07-19 |
霍夫曼-拉罗奇有限公司 |
免疫球蛋白变体及其用途
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン,エルエルシー |
抗体製剤
|
GB2466025A
(en)
|
2008-12-08 |
2010-06-09 |
Univ Francois Rabelais De Tour |
C3/ITGAM polymorphisms and cancer prognosis
|
AU2009325878B2
(en)
|
2008-12-08 |
2014-01-16 |
Compugen Ltd. |
TMEM154 polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
CN106220734A
(zh)
|
2008-12-19 |
2016-12-14 |
宏观基因有限公司 |
共价双抗体及其用途
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US8846870B2
(en)
|
2008-12-22 |
2014-09-30 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-HS6ST2 antibodies and uses thereof
|
EP3318573A1
(en)
|
2008-12-23 |
2018-05-09 |
F. Hoffmann-La Roche AG |
Mmunoglobulin variants with altered binding to protein a
|
WO2010073694A1
(ja)
|
2008-12-25 |
2010-07-01 |
国立大学法人東京大学 |
抗tm4sf20抗体を用いた癌の診断と治療
|
PT2374883T
(pt)
*
|
2008-12-26 |
2016-10-20 |
Kyowa Hakko Kirin Co Ltd |
Anticorpo anti-cd4
|
US20120014870A1
(en)
|
2008-12-26 |
2012-01-19 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody
|
US9181341B2
(en)
|
2009-01-19 |
2015-11-10 |
Innate Pharma |
Anti-KIR3D antibodies
|
WO2010084408A2
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
CA2753702C
(en)
|
2009-03-05 |
2017-01-03 |
Medarex, Inc. |
Fully human antibodies specific to cadm1
|
PE20160651A1
(es)
|
2009-03-05 |
2016-07-24 |
Abbvie Inc |
Proteinas de union a il-17
|
EP2403879A1
(en)
|
2009-03-06 |
2012-01-11 |
Kalobios Pharmaceuticals, Inc. |
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
EP3088420A1
(en)
|
2009-03-20 |
2016-11-02 |
F. Hoffmann-La Roche AG |
Bispecific anti-her antibodies
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
MX2011010012A
(es)
|
2009-03-25 |
2011-12-06 |
Genentech Inc |
NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
|
CN104788564A
(zh)
|
2009-03-25 |
2015-07-22 |
健泰科生物技术公司 |
抗-fgfr3抗体及其使用方法
|
WO2010112458A1
(en)
|
2009-03-31 |
2010-10-07 |
Novartis Ag |
Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
MX2011010158A
(es)
|
2009-04-07 |
2011-10-17 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-2/anti-c-met.
|
EP2417156B1
(en)
|
2009-04-07 |
2015-02-11 |
Roche Glycart AG |
Trivalent, bispecific antibodies
|
CA2757531A1
(en)
|
2009-04-07 |
2010-10-14 |
Roche Glycart Ag |
Bispecific anti-erbb-3/anti-c-met antibodies
|
WO2010117011A1
(ja)
|
2009-04-09 |
2010-10-14 |
第一三共株式会社 |
抗Siglec-15抗体
|
WO2010117057A1
(ja)
|
2009-04-10 |
2010-10-14 |
協和発酵キリン株式会社 |
抗tim-3抗体を用いた血液腫瘍治療法
|
US9079957B2
(en)
|
2009-04-16 |
2015-07-14 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
|
EP2421898B1
(en)
|
2009-04-20 |
2016-03-16 |
Oxford BioTherapeutics Ltd |
Antibodies specific to cadherin-17
|
ES2561081T3
(es)
|
2009-04-20 |
2016-02-24 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpo que contiene IgG2 que presenta una mutación de aminoácido introducida en el mismo
|
HUE025966T2
(en)
|
2009-04-27 |
2016-05-30 |
Kyowa Hakko Kirin Co Ltd |
Anti-IL-3RA antibody for use in the treatment of blood cancer
|
PE20120532A1
(es)
|
2009-04-27 |
2012-05-18 |
Novartis Ag |
ANTICUERPOS ANTI-ActRIIB
|
KR20120051603A
(ko)
|
2009-05-01 |
2012-05-22 |
고쿠리츠다이가쿠호징 도쿄다이가쿠 |
항카드헤린 항체
|
US9340615B2
(en)
|
2009-05-15 |
2016-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-AXL antibody
|
US8815242B2
(en)
*
|
2009-05-27 |
2014-08-26 |
Synageva Biopharma Corp. |
Avian derived antibodies
|
EP2435473B1
(en)
|
2009-05-27 |
2013-10-02 |
F.Hoffmann-La Roche Ag |
Tri- or tetraspecific antibodies
|
JP5808052B2
(ja)
|
2009-05-29 |
2015-11-10 |
中外製薬株式会社 |
Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
|
DK2438171T3
(en)
|
2009-06-02 |
2015-01-26 |
Regeneron Pharma |
Fucosylerings-deficient cells
|
WO2010143698A1
(ja)
|
2009-06-11 |
2010-12-16 |
大学共同利用機関法人情報・システム研究機構 |
タンパク質の生産方法
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
BRPI1011805A2
(pt)
|
2009-06-18 |
2016-10-11 |
Pfizer |
anticorpos anti incisura-1
|
CN102802661B
(zh)
|
2009-06-22 |
2016-01-13 |
米迪缪尼有限公司 |
用于位点特异性偶联的工程改造的Fc区
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
KR20120089253A
(ko)
|
2009-07-31 |
2012-08-09 |
제넨테크, 인크. |
Bv8? 또는 g?csf?길항제를 이용한 종양 전이의 억제
|
AR077594A1
(es)
|
2009-07-31 |
2011-09-07 |
Organon Nv |
Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
|
CN102597233B
(zh)
|
2009-08-07 |
2014-10-29 |
协和发酵麒麟株式会社 |
人源化抗淀粉样-b寡聚体抗体
|
BR112012002819B1
(pt)
|
2009-08-07 |
2022-11-22 |
Kyowa Kirin Co., Ltd |
Anticorpo humanizado antioligômero de amiloide-b, seus usos, e formulação farmacêutica
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
MA33470B1
(fr)
|
2009-08-14 |
2012-07-03 |
Hoffmann La Roche |
Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
|
AU2010285974A1
(en)
|
2009-08-17 |
2012-03-22 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
TW201113037A
(en)
|
2009-08-28 |
2011-04-16 |
Hoffmann La Roche |
Antibodies against CDCP1 for the treatment of cancer
|
EP2473532B1
(en)
|
2009-08-31 |
2017-06-21 |
Roche Glycart AG |
Affinity-matured humanized anti cea monoclonal antibodies
|
CN102612524A
(zh)
|
2009-09-01 |
2012-07-25 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
EP2473522B1
(en)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
JP5746183B2
(ja)
|
2009-09-22 |
2015-07-08 |
プロビオゲン アーゲー |
特定のグリカン構造を含有する分子を生成する方法
|
HUE036549T2
(hu)
|
2009-10-07 |
2018-07-30 |
Macrogenics Inc |
A fukozilezés mértékének megváltozása miatt javított effektor funkciót mutató, Fc-régiót tartalmazó polipeptidek, valamint eljárások alkalmazásukra
|
EP2470569A1
(en)
|
2009-10-13 |
2012-07-04 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
CN102666589B
(zh)
|
2009-10-14 |
2014-08-20 |
卡罗拜奥斯制药公司 |
EphA3抗体
|
AU2010306677B2
(en)
|
2009-10-15 |
2013-05-23 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
AU2010310585A1
(en)
|
2009-10-22 |
2012-05-03 |
Genentech, Inc. |
Anti-hepsin antibodies and methods using same
|
EP3520816B1
(en)
|
2009-10-23 |
2022-08-31 |
Takeda Pharmaceutical Company Limited |
Anti-gcc antibody molecules and related compositions and methods
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
AU2010311567B2
(en)
|
2009-10-26 |
2015-03-26 |
Chugai Seiyaku Kabushiki Kaisha |
Method for the production of a glycosylated immunoglobulin
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
EP2494061B1
(en)
|
2009-10-29 |
2017-01-25 |
Janssen Biotech, Inc. |
Antibody glycosylation variants
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
MY162511A
(en)
|
2009-11-04 |
2017-06-15 |
Merck Sharp & Dohme |
Engineered anti-tslp antibody
|
AU2010315101B2
(en)
|
2009-11-04 |
2016-01-28 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
EP2496601B1
(en)
|
2009-11-05 |
2017-06-07 |
F. Hoffmann-La Roche AG |
Methods and composition for secretion of heterologous polypeptides
|
SMT202000195T1
(it)
|
2009-11-24 |
2020-05-08 |
Medimmune Ltd |
Agenti leganti direzionati contro b7-h1
|
EP2507265B1
(en)
|
2009-12-01 |
2016-05-11 |
Compugen Ltd. |
Antibody specific for heparanase splice variant T5 and its use.
|
BR112012013734A2
(pt)
|
2009-12-08 |
2017-01-10 |
Abbott Gmbh & Co Kg |
anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
KR20120107122A
(ko)
|
2009-12-22 |
2012-09-28 |
노파르티스 아게 |
치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
|
MA33892B1
(fr)
|
2009-12-22 |
2013-01-02 |
Roche Glycart Ag |
Anticorps anti-her3, et leurs utilisations
|
WO2011079185A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
HUE056313T2
(hu)
|
2010-01-29 |
2022-02-28 |
Chugai Pharmaceutical Co Ltd |
Anti-DLL3 antitest
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
LT2535358T
(lt)
|
2010-02-10 |
2018-03-26 |
Fujifilm Ri Pharma Co., Ltd. |
Radioaktyvus metalu žymėtas anti-kadherino antikūnas
|
CN102770767A
(zh)
|
2010-02-10 |
2012-11-07 |
诺瓦提斯公司 |
用于肌肉生长的方法和组合物
|
BR112012020102A2
(pt)
|
2010-02-10 |
2016-11-29 |
Immunogen Inc |
anticorpos cd20 e usos dos mesmos.
|
DK2536748T3
(da)
|
2010-02-18 |
2014-10-13 |
Genentech Inc |
Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
US8859736B2
(en)
|
2010-02-19 |
2014-10-14 |
The Board Of Regents Of The University Of Oklahoma |
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
|
WO2011105573A1
(ja)
|
2010-02-26 |
2011-09-01 |
株式会社未来創薬研究所 |
抗icam3抗体およびその用途
|
CA2791652C
(en)
|
2010-03-02 |
2018-06-12 |
Kyowa Hakko Kirin Co., Ltd. |
Modified antibody composition
|
BR112012022210B1
(pt)
|
2010-03-04 |
2021-08-17 |
Macrogenics, Inc |
Anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
NZ602040A
(en)
|
2010-03-24 |
2014-12-24 |
Genentech Inc |
Anti-lrp6 antibodies
|
JP5767207B2
(ja)
|
2010-03-26 |
2015-08-19 |
協和発酵キリン株式会社 |
新規修飾部位導入抗体および抗体フラグメント
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
BR112012024489A2
(pt)
|
2010-03-29 |
2016-05-31 |
Zymeworks Inc |
anticorpos com função efetora suprimida ou aumentada
|
EP4501956A2
(en)
|
2010-03-30 |
2025-02-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules that promote antigen clearance
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
MX336196B
(es)
|
2010-04-15 |
2016-01-11 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
WO2011134899A1
(en)
|
2010-04-27 |
2011-11-03 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
SG185415A1
(en)
|
2010-05-06 |
2012-12-28 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
ES2949159T3
(es)
|
2010-05-06 |
2023-09-26 |
Novartis Ag |
Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
|
MX350723B
(es)
|
2010-05-14 |
2017-09-14 |
Abbvie Inc |
Proteínas de unión a il-1.
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
AU2011261161A1
(en)
|
2010-06-01 |
2013-01-10 |
Ludwig Institute For Cancer Research Limited |
Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
|
JP6048973B2
(ja)
|
2010-06-03 |
2016-12-27 |
ジェネンテック, インコーポレイテッド |
抗体及びイムノコンジュゲートのイムノpetイメージング及びこれらの使用方法
|
CA2814155C
(en)
|
2010-06-11 |
2019-10-22 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-tim-3 antibody
|
EP2582729A4
(en)
|
2010-06-18 |
2014-05-28 |
Hoffmann La Roche |
ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
|
DK3323830T3
(da)
|
2010-06-19 |
2023-09-25 |
Memorial Sloan Kettering Cancer Center |
Anti-gd2 antibodies
|
US20130189268A1
(en)
|
2010-06-22 |
2013-07-25 |
Precision Biologics, Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
US9534246B2
(en)
|
2010-07-01 |
2017-01-03 |
Glaxo Group Limited |
Method for selecting high producing cell lines
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
JP5619162B2
(ja)
|
2010-07-08 |
2014-11-05 |
本田技研工業株式会社 |
高周波加熱用コイル
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
EP2591004A1
(en)
|
2010-07-09 |
2013-05-15 |
F.Hoffmann-La Roche Ag |
Anti-neuropilin antibodies and methods of use
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
WO2012016227A2
(en)
|
2010-07-29 |
2012-02-02 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
WO2012013823A2
(en)
|
2010-07-30 |
2012-02-02 |
Glycode |
A yeast artificial chromosome carrying the mammalian glycosylation pathway
|
ES2667100T3
(es)
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Diacuerpos covalentes y sus usos
|
TW201206473A
(en)
|
2010-08-03 |
2012-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
MX2013001302A
(es)
|
2010-08-03 |
2013-03-08 |
Hoffmann La Roche |
Biomarcadores de leucemia linfocitica (cll).
|
MX2013001305A
(es)
|
2010-08-05 |
2013-03-20 |
Hoffmann La Roche |
Proteina de fusion de citoquina anti-viral de anticuerpo anti-mhc.
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
UA113712C2
(xx)
|
2010-08-13 |
2017-02-27 |
|
Антитіло до fap і способи його застосування
|
RU2584597C2
(ru)
|
2010-08-13 |
2016-05-20 |
Рош Гликарт Аг |
Антитела против а2 тенасцина с и способы их применения
|
JP6147665B2
(ja)
|
2010-08-14 |
2017-06-14 |
アッヴィ・インコーポレイテッド |
アミロイドベータ結合タンパク質
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
EA036314B1
(ru)
|
2010-08-20 |
2020-10-26 |
Новартис Аг |
Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
ES2553262T3
(es)
|
2010-08-25 |
2015-12-07 |
F. Hoffmann-La Roche Ag |
Anticuerpos contra la IL-18R1 y usos de los mismos
|
MX2013002270A
(es)
|
2010-08-26 |
2013-05-14 |
Abbvie Inc |
Inmonoglubinas de dominio variable doble y usos de las mismas.
|
CN103260646B
(zh)
|
2010-08-27 |
2016-01-13 |
施特姆森特克斯股份有限公司 |
Notum蛋白调节剂和使用方法
|
AU2011295919A1
(en)
|
2010-08-31 |
2013-03-07 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
WO2012031273A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
US8999335B2
(en)
|
2010-09-17 |
2015-04-07 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
US9068014B2
(en)
|
2010-09-23 |
2015-06-30 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2012045703A1
(en)
|
2010-10-05 |
2012-04-12 |
Novartis Ag |
Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
|
EP3020812B1
(en)
|
2010-10-29 |
2018-05-02 |
Daiichi Sankyo Company, Limited |
Novel anti-dr5 antibody
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
US8772457B2
(en)
|
2010-11-10 |
2014-07-08 |
Genentech, Inc. |
BACE1 antibodies
|
BR112013012213A2
(pt)
|
2010-11-17 |
2020-09-01 |
Chugai Seiyaku Kabushiki Kaisha |
moléculas de ligação a antígeno mul tlespecíficas tendo função alternativa à função dos fatores viii, ix e x de coagulação sanguínea, e anticorpo bies- 5 pecífico, seus usos na prevenção ou tratamento de hemorragia, ácido nucleico, vetor, célula, método para produzir as referidas moléculas de ligação, composição farmacêutica e kit
|
EA201390735A1
(ru)
*
|
2010-11-19 |
2013-12-30 |
Янссен Байотек, Инк. |
Композиции вакцин с фрагментами расщепленных иммуноглобулинов
|
SG190232A1
(en)
|
2010-11-23 |
2013-06-28 |
Glaxo Group Ltd |
Antigen binding proteins to oncostatin m (osm)
|
EP2643016A2
(en)
|
2010-11-23 |
2013-10-02 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of anemia
|
MX2013005847A
(es)
|
2010-11-24 |
2013-12-12 |
Glaxo Group Ltd |
Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
|
TWI654203B
(zh)
|
2010-11-30 |
2019-03-21 |
中外製藥股份有限公司 |
具有鈣依存性的抗原結合能力之抗體
|
KR101026999B1
(ko)
|
2010-12-08 |
2011-04-11 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
PE20171143A1
(es)
|
2010-12-08 |
2017-08-10 |
Stem Centrx Inc |
Nuevos moduladores y metodos para su uso
|
WO2012076670A2
(en)
|
2010-12-10 |
2012-06-14 |
Novartis Ag |
Antibody formulation
|
WO2012080926A2
(en)
|
2010-12-15 |
2012-06-21 |
Wyeth Llc |
Anti-notch1 antibodies
|
AU2011342161C1
(en)
|
2010-12-15 |
2016-03-17 |
Kyowa Kirin Co., Ltd. |
Process for production of protein
|
EP2653541B1
(en)
|
2010-12-15 |
2017-11-08 |
Kyowa Hakko Kirin Co., Ltd. |
Method for producing proteins
|
BR112013013460A8
(pt)
|
2010-12-16 |
2019-02-12 |
Genentech Inc |
métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total
|
JP2014507384A
(ja)
|
2010-12-16 |
2014-03-27 |
ロシュ グリクアート アーゲー |
Mdm2阻害剤とのアフコシル化cd20抗体の併用療法
|
MX345519B
(es)
|
2010-12-20 |
2017-02-01 |
Genentech Inc |
Anticuerpos anti-mesotelina e inmunoconjugados.
|
SG10201604699VA
(en)
|
2010-12-21 |
2016-07-28 |
Abbvie Inc |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
TW201307391A
(zh)
|
2010-12-22 |
2013-02-16 |
Genentech Inc |
抗-pcsk9抗體及其使用方法
|
CA2822366A1
(en)
|
2010-12-23 |
2012-06-28 |
Janssen Biotech, Inc. |
Active protease-resistant antibody fc mutants
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
US20120189633A1
(en)
|
2011-01-26 |
2012-07-26 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
FR2971250A1
(fr)
|
2011-02-07 |
2012-08-10 |
Univ Nantes |
Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
|
BR112013019083A2
(pt)
|
2011-02-10 |
2017-04-04 |
Roche Glycart Ag |
combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
CA2825081A1
(en)
|
2011-02-28 |
2012-09-07 |
Birgit Bossenmaier |
Antigen binding proteins
|
KR101572338B1
(ko)
|
2011-02-28 |
2015-11-26 |
에프. 호프만-라 로슈 아게 |
1가 항원 결합 단백질
|
CA2827722C
(en)
|
2011-03-02 |
2020-05-12 |
Roche Glycart Ag |
Anti-cea antibodies
|
EP2895592A1
(en)
|
2011-03-23 |
2015-07-22 |
Société Industrielle Limousine d'Application Biologique (SILAB) |
A yeast recombinant cell capable of producing gdp-fucose
|
RU2607014C2
(ru)
|
2011-03-29 |
2017-01-10 |
Рош Гликарт Аг |
Fc варианты антитела
|
KR20140021589A
(ko)
|
2011-04-07 |
2014-02-20 |
제넨테크, 인크. |
항-fgfr4 항체 및 사용 방법
|
CA2830923A1
(en)
|
2011-04-15 |
2012-10-18 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
US20140193420A1
(en)
|
2011-04-18 |
2014-07-10 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-itm2a antibody
|
HUE034276T2
(en)
|
2011-04-19 |
2018-02-28 |
Merrimack Pharmaceuticals Inc |
Bispecific anti-IGF-1R and anti-ErbB3 antibodies
|
PL2703486T3
(pl)
|
2011-04-25 |
2018-07-31 |
Daiichi Sankyo Company, Limited |
Przeciwciało anty-b7-h3
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
WO2012155019A1
(en)
|
2011-05-12 |
2012-11-15 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
ES2657862T3
(es)
|
2011-05-13 |
2018-03-07 |
Gamamabs Pharma |
Anticuerpos contra HER3
|
EP3219730A1
(en)
|
2011-05-16 |
2017-09-20 |
F. Hoffmann-La Roche AG |
Fgfr1 agonists and methods of use
|
AU2012259162C1
(en)
|
2011-05-21 |
2020-05-21 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
SG195082A1
(en)
|
2011-05-25 |
2013-12-30 |
Innate Pharma Sa |
Anti-kir antibodies for the treatment of inflammatory disorders
|
PH12013502421A1
(en)
|
2011-05-27 |
2014-01-06 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17) -binding proteins
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
EP2718325A4
(en)
|
2011-06-13 |
2015-03-11 |
ABGENOMICS COöPERATIEF U A |
ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
MX343117B
(es)
|
2011-06-15 |
2016-10-25 |
Hoffmann La Roche |
Anticuerpos del receptor eritropoyetina (epo) anti-humana y metodos de uso.
|
EP2721073A1
(en)
|
2011-06-16 |
2014-04-23 |
Novartis AG |
Soluble proteins for use as therapeutics
|
CA2840461A1
(en)
|
2011-06-20 |
2012-12-27 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-erbb3 antibody
|
US20140120555A1
(en)
*
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
WO2012175691A1
(en)
|
2011-06-22 |
2012-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-axl antibodies and uses thereof
|
ES2677367T3
(es)
|
2011-06-22 |
2018-08-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anticuerpos anti-Axl y usos de los mismos
|
FR2976811A1
(fr)
|
2011-06-22 |
2012-12-28 |
Lfb Biotechnologies |
Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
|
ES2667864T3
(es)
|
2011-06-22 |
2018-05-14 |
F. Hoffmann-La Roche Ag |
Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I
|
MX347424B
(es)
|
2011-06-28 |
2017-04-26 |
Oxford Biotherapeutics Ltd |
Anticuerpos para la ciclasa 2 adp-ribosil.
|
HUE033713T2
(en)
|
2011-06-28 |
2017-12-28 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
AR086823A1
(es)
|
2011-06-30 |
2014-01-22 |
Genentech Inc |
Formulaciones de anticuerpo anti-c-met, metodos
|
EP2726503B1
(en)
|
2011-06-30 |
2019-09-04 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
SI2726099T1
(sl)
|
2011-07-01 |
2018-11-30 |
Novartis Ag |
Postopek za zdravljenje metaboličnih motenj
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
RU2640025C2
(ru)
|
2011-07-13 |
2017-12-25 |
Эббви Инк. |
Способы и композиции для лечения астмы с использованием антител против il-13
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
MX2014001019A
(es)
|
2011-07-27 |
2014-05-13 |
Glaxo Group Ltd |
Dominios variables singulares anti-vgf fusionados con dominios de fc.
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
CN103890008A
(zh)
|
2011-08-17 |
2014-06-25 |
霍夫曼-拉罗奇有限公司 |
在顽固性肿瘤中抑制血管发生
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
PL2748202T3
(pl)
|
2011-08-23 |
2018-12-31 |
Roche Glycart Ag |
Dwuswoiste cząsteczki wiążące antygen
|
EP2748195A1
(en)
|
2011-08-23 |
2014-07-02 |
Roche Glycart AG |
Anti-mcsp antibodies
|
AU2012300279A1
(en)
|
2011-08-26 |
2014-04-03 |
Merrimack Pharmaceuticals, Inc. |
Tandem Fc bispecific antibodies
|
BR112014005720A2
(pt)
|
2011-09-15 |
2017-12-12 |
Genentech Inc |
método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
|
CN103930111A
(zh)
|
2011-09-19 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
包含c-met拮抗剂和b-raf拮抗剂的组合治疗
|
MX2014002996A
(es)
|
2011-09-23 |
2014-05-28 |
Roche Glycart Ag |
Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
|
ES2925654T3
(es)
|
2011-09-30 |
2022-10-19 |
Dana Farber Cancer Inst Inc |
Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
HK1198813A1
(en)
|
2011-09-30 |
2015-06-12 |
中外制药株式会社 |
Antigen-binding molecule inducing immune response to target antigen
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
MX2014004074A
(es)
|
2011-10-05 |
2014-06-05 |
Genentech Inc |
Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
|
CA2851534C
(en)
|
2011-10-10 |
2023-02-14 |
Xencor, Inc. |
A method for purifying antibodies
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
RS57645B1
(sr)
|
2011-10-14 |
2018-11-30 |
Hoffmann La Roche |
Anti-htra1 antitela i načini primene
|
JP2014530816A
(ja)
|
2011-10-14 |
2014-11-20 |
ノバルティスアーゲー |
Wnt経路関連疾患のための抗体および方法
|
WO2013056148A2
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
SG11201401791WA
(en)
|
2011-10-24 |
2014-08-28 |
Abbvie Inc |
Immunobinders directed against sclerostin
|
KR20140097205A
(ko)
|
2011-10-28 |
2014-08-06 |
제넨테크, 인크. |
흑색종을 치료하는 치료 조합물 및 방법
|
WO2013062083A1
(ja)
|
2011-10-28 |
2013-05-02 |
ファーマロジカルズ・リサーチ プライベート リミテッド |
癌幹細胞特異的分子
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
HK1201855A1
(en)
|
2011-11-01 |
2015-09-11 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
US10598653B2
(en)
|
2011-11-01 |
2020-03-24 |
Bionomics Inc. |
Methods of blocking cancer stem cell growth
|
PT2773671T
(pt)
|
2011-11-04 |
2021-12-14 |
Zymeworks Inc |
Geração de anticorpo heterodimérico estável com mutações no domínio fc
|
JP2014533249A
(ja)
|
2011-11-07 |
2014-12-11 |
メディミューン,エルエルシー |
多重特異性を持つ多価結合タンパク質およびその使用
|
MX2014005885A
(es)
|
2011-11-21 |
2014-09-04 |
Genentech Inc |
Purificacion de anticuerpos anti-c-met.
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
EP3590538A1
(en)
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3)
|
BR112014013568A2
(pt)
|
2011-12-05 |
2017-06-13 |
Novartis Ag |
anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
|
WO2013083497A1
(en)
|
2011-12-06 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
WO2013087789A1
(en)
|
2011-12-13 |
2013-06-20 |
Glykos Finland Ltd. |
Antibody isoform arrays and methods thereof
|
PT2794905T
(pt)
|
2011-12-20 |
2020-06-30 |
Medimmune Llc |
Polipéptidos modificados para estrutura de anticorpos bispecíficos
|
EA201491214A1
(ru)
|
2011-12-21 |
2015-02-27 |
Новартис Аг |
Композиции и способы применения антител, нацеленных на фактор p
|
CN107881196A
(zh)
|
2011-12-22 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
SG10201700169PA
(en)
|
2011-12-22 |
2017-02-27 |
Hoffmann La Roche |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
HK1200849A1
(en)
|
2011-12-22 |
2015-08-14 |
F. Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
EP2797955A2
(en)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Dual variable domain immunoglobulins against il-13 and/or il-17
|
EP3663314A1
(en)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
BR112014017518A2
(pt)
|
2012-01-18 |
2018-09-04 |
Genentech Inc |
anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
|
US20130183294A1
(en)
|
2012-01-18 |
2013-07-18 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
DK2807192T3
(en)
|
2012-01-27 |
2018-07-23 |
Abbvie Deutschland |
COMPOSITION AND PROCEDURE FOR DIAGNOSTICATION AND TREATMENT OF DISEASES RELATED TO NEURITE DEGENERATION
|
BR112014018471A2
(pt)
|
2012-01-31 |
2017-07-04 |
Genentech Inc |
anticorpos anti-ige m1' e métodos para o seu uso
|
BR112014018481A2
(pt)
|
2012-02-01 |
2017-07-04 |
Compugen Ltd |
anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
|
AU2013218017B2
(en)
|
2012-02-07 |
2017-12-07 |
Innate Pharma |
MICA binding agents
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
BR112014019741A2
(pt)
|
2012-02-11 |
2020-12-22 |
Genentech, Inc |
Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
|
RU2624128C2
(ru)
|
2012-02-15 |
2017-06-30 |
Ф. Хоффманн-Ля Рош Аг |
Аффинная хроматография с применением fc-рецепторов
|
US9228006B2
(en)
|
2012-03-16 |
2016-01-05 |
University Health Network |
Methods and compositions for modulating Toso activity
|
KR20140148388A
(ko)
|
2012-03-27 |
2014-12-31 |
제넨테크, 인크. |
Her3 억제제와 관련된 진단 및 치료
|
JP6280031B2
(ja)
|
2012-03-29 |
2018-02-14 |
中外製薬株式会社 |
抗lamp5抗体およびその利用
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
MX2014011826A
(es)
|
2012-03-30 |
2014-11-21 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-siglec-15 novedoso.
|
CA2868959A1
(en)
|
2012-03-30 |
2013-10-03 |
Daiichi Sankyo Company, Limited |
Cdr-modified anti-siglec-15 antibody
|
US9714298B2
(en)
|
2012-04-09 |
2017-07-25 |
Daiichi Sankyo Company, Limited |
Anti-FGFR2 antibodies and methods of use thereof for treating cancer
|
WO2013155346A1
(en)
|
2012-04-11 |
2013-10-17 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
TWI606065B
(zh)
|
2012-04-27 |
2017-11-21 |
第一三共股份有限公司 |
抗robo4抗體
|
JP6242865B2
(ja)
|
2012-05-01 |
2017-12-06 |
ジェネンテック, インコーポレイテッド |
抗pmel17抗体および免疫複合体
|
WO2013166594A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
MX2014014086A
(es)
|
2012-05-23 |
2015-01-26 |
Genentech Inc |
Metodo de seleccion para agentes terapeuticos.
|
WO2013174927A1
(en)
|
2012-05-23 |
2013-11-28 |
Novartis International Pharmaceutical Limited |
Production of fucosylated glycoproteins
|
RU2014149681A
(ru)
|
2012-05-24 |
2016-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Антитела с множественной специфичностью
|
KR20150016579A
(ko)
|
2012-05-30 |
2015-02-12 |
추가이 세이야쿠 가부시키가이샤 |
표적 조직 특이적 항원 결합 분자
|
WO2013184514A1
(en)
|
2012-06-04 |
2013-12-12 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th2 세포 전환용 에피토프 및 이의 용도
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
AR091462A1
(es)
|
2012-06-15 |
2015-02-04 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
|
EP2864352B1
(en)
|
2012-06-22 |
2018-08-08 |
The Trustees Of Dartmouth College |
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
BR112014030844A2
(pt)
|
2012-07-04 |
2019-10-15 |
Hoffmann La Roche |
anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
|
NZ701040A
(en)
|
2012-07-04 |
2017-02-24 |
Hoffmann La Roche |
Covalently linked antigen-antibody conjugates
|
RU2017128512A
(ru)
|
2012-07-04 |
2019-02-15 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к теофиллину и способы их применения
|
PL2870247T3
(pl)
|
2012-07-05 |
2019-10-31 |
Hoffmann La Roche |
Układ ekspresji i wydzielania
|
EP2870973B1
(en)
|
2012-07-06 |
2022-08-31 |
St. Marianna University School of Medicine |
Remedy for htlv-1-associated myelopathy patients
|
BR112015000439A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação
|
AR091702A1
(es)
|
2012-07-09 |
2015-02-25 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados
|
CA2873889A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Anti-cd22 antibodies and immunoconjugates
|
HK1209042A1
(en)
|
2012-07-09 |
2016-03-24 |
基因泰克公司 |
Immunoconjugates comprising anti-cd79b antibodies
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
CA2874554C
(en)
|
2012-07-13 |
2019-12-03 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
NZ731881A
(en)
|
2012-07-25 |
2022-07-29 |
Celldex Therapeutics Inc |
Anti-kit antibodies and uses thereof
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
SG11201407580YA
(en)
|
2012-08-07 |
2014-12-30 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
WO2014029752A1
(en)
|
2012-08-22 |
2014-02-27 |
Glaxo Group Limited |
Anti lrp6 antibodies
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CN109793893B
(zh)
|
2012-09-07 |
2023-05-26 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
EP2902489B9
(en)
|
2012-09-27 |
2018-02-07 |
Chugai Seiyaku Kabushiki Kaisha |
Fgfr3 fusion gene and pharmaceutical drug targeting same
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
DK2907824T3
(en)
|
2012-10-11 |
2018-07-23 |
Daiichi Sankyo Co Ltd |
ANTIBODY-drug conjugate
|
ES2782248T3
(es)
|
2012-10-19 |
2020-09-11 |
Daiichi Sankyo Co Ltd |
Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
|
CN104884472B
(zh)
|
2012-11-01 |
2021-10-15 |
艾伯维公司 |
抗-vegf/dll4双重可变结构域免疫球蛋白及其用途
|
US10344099B2
(en)
|
2012-11-05 |
2019-07-09 |
Zenyaku Kogyo Kabushikikaisha |
Antibody and antibody composition production method
|
HK1214830A1
(zh)
|
2012-11-05 |
2016-08-05 |
Foundation Medicine, Inc. |
新型ntrk1融合分子及其应用
|
AU2013337264B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
AR093378A1
(es)
|
2012-11-08 |
2015-06-03 |
Hoffmann La Roche |
PROTEINAS LIGANTES DE ANTIGENO HER3 DE UNION A LA HORQUILLA b DE HER3
|
EA201590731A1
(ru)
|
2012-11-13 |
2015-11-30 |
Дженентек, Инк. |
Антитела к гемагглютинину и способы применения
|
EP2733153A1
(en)
|
2012-11-15 |
2014-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the preparation of immunoconjugates and uses thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
SMT201900242T1
(it)
|
2012-12-03 |
2019-05-10 |
Bristol Myers Squibb Co |
Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
|
HRP20210517T1
(hr)
|
2012-12-05 |
2021-05-14 |
Novartis Ag |
Pripravci i postupci za protutijela usmjerena na epo
|
SG11201504106XA
(en)
|
2012-12-06 |
2015-07-30 |
Univ Kanazawa Nat Univ Corp |
Therapeutic method for mesothelioma
|
TWI614266B
(zh)
|
2012-12-07 |
2018-02-11 |
Kyowa Hakko Kirin Co Ltd |
抗folr1抗體
|
CA2894225A1
(fr)
|
2012-12-17 |
2014-06-26 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
MA37961A1
(fr)
|
2012-12-18 |
2016-06-30 |
Glycotope Gmbh |
Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation
|
EP4119947A1
(en)
|
2012-12-21 |
2023-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
|
TWI693073B
(zh)
|
2012-12-21 |
2020-05-11 |
日商中外製藥股份有限公司 |
對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
CN104884474A
(zh)
|
2012-12-21 |
2015-09-02 |
弗·哈夫曼-拉罗切有限公司 |
包含i类mhc的二硫键连接多价多功能蛋白质
|
CA2896723C
(en)
|
2012-12-28 |
2024-02-13 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
US9458244B2
(en)
|
2012-12-28 |
2016-10-04 |
Abbvie Inc. |
Single chain multivalent binding protein compositions and methods
|
WO2014106004A2
(en)
|
2012-12-28 |
2014-07-03 |
Abbvie, Inc. |
High-throughput system and method for identifying antibodies having specific antigen binding activities
|
EA201500741A1
(ru)
|
2013-01-10 |
2016-01-29 |
Генмаб Б.В. |
ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116596A1
(en)
|
2013-01-22 |
2014-07-31 |
Abbvie, Inc. |
Methods for optimizing domain stability of binding proteins
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
WO2014122144A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
|
BR112015018899B1
(pt)
|
2013-02-08 |
2023-09-26 |
Novartis Ag |
Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira
|
CN105073775B
(zh)
|
2013-02-08 |
2019-03-19 |
诺华股份有限公司 |
抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
ES2747920T3
(es)
|
2013-02-14 |
2020-03-12 |
Innate Pharma |
Anticuerpo anti-NKP46 para diagnóstico de un linfoma de células T periféricas no cutáneo (PTCL)
|
ES2730011T3
(es)
|
2013-02-20 |
2019-11-07 |
Innate Pharma |
Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
|
HK1211235A1
(en)
|
2013-02-22 |
2016-05-20 |
霍夫曼-拉罗奇有限公司 |
Methods of treating cancer and preventing drug resistance
|
EP2958905B1
(en)
|
2013-02-22 |
2017-03-29 |
Amgen Inc. |
Carbohydrate phosphonate derivatives as modulators of glycosylation
|
MX2015010789A
(es)
|
2013-02-26 |
2015-11-26 |
Roche Glycart Ag |
Anticuerpos anti-pcsm.
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
BR112015021462A2
(pt)
|
2013-03-06 |
2017-10-10 |
Adimab Llc |
anticorpos biespecíficos anti-c-met tandem fc
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
WO2014142117A1
(ja)
|
2013-03-12 |
2014-09-18 |
全薬工業株式会社 |
抗ブドウ球菌抗体、その製造方法並びにその使用
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
CN105189552B
(zh)
|
2013-03-14 |
2019-08-02 |
基因泰克公司 |
抗b7-h4抗体和免疫缀合物
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
CA2906421C
(en)
|
2013-03-14 |
2022-08-16 |
George J. Dawson |
Hcv antigen-antibody combination assay and methods and compositions for use therein
|
WO2014153030A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
EP2970947A4
(en)
|
2013-03-14 |
2016-10-12 |
Abbott Lab |
RECOMBINANT HCV NS3 ANTIGENS AND THEIR MUTANTS FOR ENHANCED ANTIBODY DETECTION
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
JP6739329B2
(ja)
|
2013-03-14 |
2020-08-12 |
アボット・ラボラトリーズAbbott Laboratories |
Hcvコア脂質結合ドメインモノクローナル抗体
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
TWI658051B
(zh)
|
2013-03-15 |
2019-05-01 |
葛蘭素史密斯克藍智慧財產發展有限公司 |
抗原結合蛋白
|
CN105377889B
(zh)
|
2013-03-15 |
2020-07-17 |
Xencor股份有限公司 |
异二聚体蛋白
|
EP3666886A1
(en)
|
2013-03-15 |
2020-06-17 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
US9260527B2
(en)
|
2013-03-15 |
2016-02-16 |
Sdix, Llc |
Anti-human CXCR4 antibodies and methods of making same
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
CA2902910A1
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
CN105705165B
(zh)
|
2013-03-15 |
2020-04-24 |
纪念斯隆-凯特琳癌症中心 |
高亲和力抗gd2抗体
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
NZ751264A
(en)
|
2013-03-15 |
2021-07-30 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
AU2014235474B2
(en)
|
2013-03-15 |
2017-05-25 |
Novartis Ag |
Antibody drug conjugates
|
MX368005B
(es)
|
2013-03-15 |
2019-09-13 |
Genentech Inc |
Polipéptidos de il-22 y proteínas de fusion de il-22 fc y métodos de uso.
|
SG10201706210WA
(en)
|
2013-03-15 |
2017-09-28 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
BR112015021521A2
(pt)
|
2013-03-15 |
2017-10-10 |
Genentech Inc |
anticorpos anti-crth2 e métodos para seu uso
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
US20160068609A1
(en)
|
2013-04-22 |
2016-03-10 |
Glycotope Gmbh |
Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
|
HK1213577A1
(zh)
|
2013-04-29 |
2016-07-08 |
豪夫迈‧罗氏有限公司 |
消除对fcrn-结合的抗-igf-1r抗体及其在血管性眼病治疗中的用途
|
CA2904806C
(en)
|
2013-04-29 |
2021-11-23 |
F. Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
JP6618893B2
(ja)
|
2013-04-29 |
2019-12-11 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Fc受容体結合が変更された非対称抗体および使用方法
|
MA38632B1
(fr)
|
2013-05-20 |
2019-10-31 |
Genentech Inc |
Anticorps anti-récepteur de transferrine et procédés d'utilisation
|
RS60256B1
(sr)
|
2013-05-31 |
2020-06-30 |
Genentech Inc |
Antitela i konjugati protiv teihoinske kiseline zida
|
WO2014193722A1
(en)
|
2013-05-31 |
2014-12-04 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
US20160159919A1
(en)
|
2013-06-24 |
2016-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic Agent Comprising Humanized Anti-Epiregulin Antibody as Active Ingredient for Non-Small-Cell Lung Carcinoma Excluding Adenocarcinoma
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
SG11201600767UA
(en)
|
2013-08-01 |
2016-03-30 |
Five Prime Therapeutics Inc |
Afucosylated anti-fgfr2iiib antibodies
|
PL3031826T3
(pl)
|
2013-08-09 |
2019-03-29 |
Toray Industries, Inc. |
Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
|
PE20160192A1
(es)
|
2013-08-12 |
2016-04-27 |
Genentech Inc |
Composiciones y metodo para tratar condiciones asociadas con el complemento
|
EP3033101B1
(en)
|
2013-08-12 |
2018-12-19 |
AstraZeneca AB |
Methods for reducing exacerbation rates of asthma using benralizumab
|
PL3033104T3
(pl)
|
2013-08-12 |
2019-09-30 |
Astrazeneca Ab |
Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu
|
MX368474B
(es)
|
2013-08-12 |
2019-10-04 |
Astrazeneca Ab |
Uso de benralizumab para mejorar síntomas de asma.
|
RU2016108652A
(ru)
|
2013-08-14 |
2017-09-14 |
Новартис Аг |
Способы лечения спорадического миозита с тельцами включений
|
US20160251410A1
(en)
|
2013-09-03 |
2016-09-01 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Compositions and methods for expressing recombinant polypeptides
|
KR20160055252A
(ko)
|
2013-09-17 |
2016-05-17 |
제넨테크, 인크. |
항-lgr5 항체의 사용 방법
|
MX2016003643A
(es)
|
2013-09-30 |
2016-12-20 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-lps o11.
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
HRP20201373T1
(hr)
|
2013-10-02 |
2020-11-27 |
Medimmune, Llc |
Neutralizacijska protutijela protiv influence a i njihova upotreba
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
KR20160066024A
(ko)
|
2013-10-08 |
2016-06-09 |
다이이찌 산쿄 가부시키가이샤 |
항 fgfr2 항체와 타제의 조합
|
EP3055328A1
(en)
|
2013-10-11 |
2016-08-17 |
F. Hoffmann-La Roche AG |
Nsp4 inhibitors and methods of use
|
MX2016003593A
(es)
|
2013-10-11 |
2016-06-02 |
Hoffmann La Roche |
Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
|
SG11201602460QA
(en)
|
2013-10-11 |
2016-04-28 |
Oxford Biotherapeutics Ltd |
Conjugated antibodies against ly75 for the treatment of cancer
|
EP3054987B1
(en)
|
2013-10-11 |
2019-10-09 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Tem8 antibodies and their use
|
AU2014334563A1
(en)
*
|
2013-10-15 |
2016-04-07 |
Astrazeneca Ab |
Methods for treating Chronic Obstructive Pulmonary disease using benralizumab
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
RU2016114074A
(ru)
|
2013-10-18 |
2017-11-23 |
Дженентек, Инк. |
Анти-rspo антитела и способы применения
|
MX2016005159A
(es)
|
2013-10-23 |
2016-07-05 |
Genentech Inc |
Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
|
PL3066124T4
(pl)
|
2013-11-07 |
2021-08-16 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Neuregulina-allosteryczne przeciwciała przeciwko ludzkiemu her3
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
CN111499743B
(zh)
|
2013-11-21 |
2024-01-12 |
豪夫迈·罗氏有限公司 |
抗-α-突触核蛋白抗体及使用方法
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
EA201691154A1
(ru)
|
2013-12-04 |
2016-10-31 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающие молекулы, активность связывания антигена которых варьируется в зависимости от концентрации соединений, и библиотеки указанных молекул
|
CA2932767A1
(en)
|
2013-12-06 |
2015-06-11 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
PL3079719T3
(pl)
|
2013-12-09 |
2020-05-18 |
Allakos Inc. |
Przeciwciała anty-Singlec-8 i sposoby ich zastosowania
|
CA2931340A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
WO2015095423A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
RU2016128726A
(ru)
|
2013-12-17 |
2018-01-23 |
Дженентек, Инк. |
Способы лечения злокачественных опухолей с использованием антагонистов связывания по оси pd-1 и антитела против cd20
|
KR20230132612A
(ko)
|
2013-12-17 |
2023-09-15 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
CN112353943A
(zh)
|
2013-12-17 |
2021-02-12 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
|
EP3083693B1
(en)
|
2013-12-20 |
2022-09-21 |
Intervet International B.V. |
Antagonistic anti-canine pd-1 antibodies
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
HRP20220748T1
(hr)
|
2013-12-24 |
2022-09-02 |
Janssen Pharmaceutica Nv |
Anti-vista antitijela i fragmenti
|
JP6130517B2
(ja)
|
2013-12-25 |
2017-05-17 |
第一三共株式会社 |
抗trop2抗体−薬物コンジュゲート
|
CA3190793A1
(en)
|
2013-12-26 |
2015-07-02 |
Mitsubishi Tanabe Pharma Corporation |
Human anti-il-33 neutralizing monoclonal antibody
|
JP6514645B2
(ja)
|
2013-12-27 |
2019-05-15 |
中外製薬株式会社 |
Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
MX373017B
(es)
|
2014-01-03 |
2020-04-28 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
PL3089996T3
(pl)
|
2014-01-03 |
2021-12-13 |
F. Hoffmann-La Roche Ag |
Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
|
MX373856B
(es)
|
2014-01-03 |
2020-03-25 |
Hoffmann La Roche |
Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
|
PL3092251T3
(pl)
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
CA2931986A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
FR3016633B1
(fr)
|
2014-01-17 |
2018-04-13 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Immunoglobuline anti-toxine du charbon
|
WO2015110923A2
(en)
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
BR112016015693A2
(pt)
|
2014-01-24 |
2017-10-24 |
Genentech Inc |
método para tratar um câncer de próstata e anticorpo
|
PT3466976T
(pt)
|
2014-01-31 |
2021-10-27 |
Daiichi Sankyo Co Ltd |
Conjugado de anticorpo anti-her2-fármaco
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
JP6702878B2
(ja)
|
2014-02-08 |
2020-06-03 |
ジェネンテック, インコーポレイテッド |
アルツハイマー病を治療する方法
|
SG10201913637RA
(en)
|
2014-02-08 |
2020-03-30 |
Genentech Inc |
Methods of treating alzheimer's disease
|
AR099465A1
(es)
|
2014-02-12 |
2016-07-27 |
Genentech Inc |
Anticuerpos anti-jagged1 y métodos de uso
|
CN106029693A
(zh)
|
2014-02-21 |
2016-10-12 |
豪夫迈·罗氏有限公司 |
抗il-13/il-17双特异性抗体及其用途
|
TWI558399B
(zh)
|
2014-02-26 |
2016-11-21 |
美國禮來大藥廠 |
癌症之組合療法
|
JP6825909B2
(ja)
|
2014-02-28 |
2021-02-03 |
アラコス インコーポレイテッド |
シグレック−8関連疾患を処置するための方法および組成物
|
TW201622744A
(zh)
|
2014-03-04 |
2016-07-01 |
美國禮來大藥廠 |
癌症之組合療法
|
US20150250853A1
(en)
|
2014-03-07 |
2015-09-10 |
University Health Network |
Methods and compositions for modifying the immune response
|
CN106659800A
(zh)
|
2014-03-12 |
2017-05-10 |
诺华股份有限公司 |
用于修饰抗体以制备免疫缀合物的特定位点
|
RU2684703C2
(ru)
|
2014-03-14 |
2019-04-11 |
Иннейт Фарма |
Гуманизированные антитела с повышенной стабильностью
|
PL3116999T3
(pl)
|
2014-03-14 |
2021-12-27 |
F.Hoffmann-La Roche Ag |
Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
|
JP2017510631A
(ja)
|
2014-03-14 |
2017-04-13 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
癌に対しnkg2d経路機能を回復させるためのワクチン組成物および方法
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
RU2016141267A
(ru)
|
2014-03-21 |
2018-04-24 |
Эббви Инк. |
Антитела против egfr и конъюгаты антитело-лекарственное средство
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
CR20160506A
(es)
|
2014-03-28 |
2017-03-10 |
Xencor Inc |
Anticuerpos biespecíficos que se unen a cd38 y cd3
|
SI3126394T1
(sl)
|
2014-03-31 |
2020-01-31 |
F. Hoffmann-La Roche Ag |
Protitelesa proti OX40 in postopki uporabe
|
KR20160146747A
(ko)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
KR101660580B1
(ko)
*
|
2014-04-02 |
2016-09-28 |
프레스티지 바이오파마 피티이. 엘티디. |
항체의 당 함량 조절을 통한 항체의 제조 방법
|
KR102186027B1
(ko)
|
2014-04-10 |
2020-12-03 |
다이이치 산쿄 유럽 게엠베하 |
항her3 항체-약물 콘주게이트
|
TW201542594A
(zh)
|
2014-04-11 |
2015-11-16 |
Medimmune Llc |
雙特異性her2抗體
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
EP3141603A4
(en)
|
2014-05-08 |
2017-12-27 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
|
KR20170003582A
(ko)
|
2014-05-22 |
2017-01-09 |
제넨테크, 인크. |
항-gpc3 항체 및 면역접합체
|
BR112016025040A2
(pt)
|
2014-05-23 |
2018-02-20 |
Genentech Inc |
métodos para determinar a expressão de biomarcador mit, para tratar câncer, para identificar um indivíduo com câncer, para predizer se um indivíduo com câncer tem mais ou menos probabilidade de responder efetivamente ao tratamento, para inibir a proliferação de uma célula e para tratar nccrcc em um indivíduo
|
SG11201609959UA
(en)
|
2014-05-30 |
2016-12-29 |
Henlius Biotech Co Ltd |
Anti-epidermal growth factor receptor (egfr) antibodies
|
MY191346A
(en)
|
2014-06-03 |
2022-06-17 |
Xbiotech Inc |
Compositions and methods for treating and preventing staphylococcus aureus infections
|
WO2015187835A2
(en)
|
2014-06-06 |
2015-12-10 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CA2951885C
(en)
|
2014-06-11 |
2023-07-04 |
Kathy A. Green |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
WO2015191715A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
JP2017517552A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック, インコーポレイテッド |
抗癌剤耐性の治療及び防止方法
|
MX384037B
(es)
|
2014-06-26 |
2025-03-14 |
Hoffmann La Roche |
Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
|
EP3161002A1
(en)
|
2014-06-27 |
2017-05-03 |
Innate Pharma |
MULTISPECIFIC NKp46 BINDING PROTEINS
|
US11208480B2
(en)
|
2014-06-27 |
2021-12-28 |
Innate Pharma |
Multispecific antigen binding proteins
|
RU2017103289A
(ru)
|
2014-07-11 |
2018-08-14 |
Дженентек, Инк. |
Ингибирование пути notch
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
WO2016012468A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
|
AU2015292326A1
(en)
|
2014-07-24 |
2017-02-23 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
WO2016020880A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
US9988443B2
(en)
|
2014-08-07 |
2018-06-05 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
TW201609099A
(zh)
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
EP3179992B1
(en)
|
2014-08-11 |
2022-05-11 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
|
KR20170040249A
(ko)
|
2014-08-12 |
2017-04-12 |
노파르티스 아게 |
항-cdh6 항체 약물 접합체
|
CR20170060A
(es)
|
2014-08-19 |
2017-04-18 |
Merck Sharp & Dohme |
Anticuerpos anti tigit
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
MX2017002605A
(es)
|
2014-08-28 |
2017-05-19 |
Bioatla Llc |
Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas.
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
AR101848A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos de anti-b7-h4 e inmunoconjugados
|
JP6886398B2
(ja)
|
2014-09-12 |
2021-06-16 |
ジェネンテック, インコーポレイテッド |
Anti−cll−1抗体及び免疫複合体
|
MA40576B1
(fr)
|
2014-09-12 |
2020-11-30 |
Genentech Inc |
Anticorps et immunoconjugués anti-her2
|
MX2017003472A
(es)
|
2014-09-17 |
2017-10-31 |
Genentech Inc |
Inmunoconjugados que comprenden anticuerpos anti-her2.
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
US10894818B2
(en)
|
2014-10-03 |
2021-01-19 |
Massachusetts Institute Of Technology |
Antibodies that bind Ebola glycoprotein and uses thereof
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
SG11201701388UA
(en)
|
2014-10-23 |
2017-03-30 |
Innate Pharma |
Treatment of cancers using anti-nkg2a agents
|
WO2016070001A1
(en)
|
2014-10-31 |
2016-05-06 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
AU2015343337A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Assays for detecting T cell immune subsets and methods of use thereof
|
BR112017009159A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
|
JP6877350B2
(ja)
|
2014-11-05 |
2021-05-26 |
ジェネンテック, インコーポレイテッド |
抗fgfr2/3抗体及びその使用方法
|
CA2960569A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-Laroche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
RU2017119428A
(ru)
|
2014-11-06 |
2018-12-06 |
Дженентек, Инк. |
Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
|
DK3215528T3
(da)
|
2014-11-06 |
2019-10-07 |
Hoffmann La Roche |
Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
BR112017009728A2
(pt)
|
2014-11-10 |
2018-02-06 |
Genentech, Inc. |
anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
|
AR102649A1
(es)
|
2014-11-14 |
2017-03-15 |
Novartis Ag |
Anticuerpos anti-cadherina-p y conjugados anticuerpos-fármacos
|
EP3875481B1
(en)
|
2014-11-14 |
2025-01-22 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
KR20170096112A
(ko)
|
2014-11-17 |
2017-08-23 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
FI3699198T3
(fi)
|
2014-11-17 |
2025-04-30 |
Regeneron Pharma |
Menetelmiä kasvaimen hoitoon bispesifistä CD3XCD20-vasta-ainetta käyttämällä
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
EP3845565A3
(en)
|
2014-11-19 |
2021-09-08 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
SG11201704056XA
(en)
|
2014-11-20 |
2017-06-29 |
Hoffmann La Roche |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
EP3221363B1
(en)
|
2014-11-21 |
2020-05-06 |
Bristol-Myers Squibb Company |
Antibodies against cd73 and uses thereof
|
ES2826566T3
(es)
|
2014-11-21 |
2021-05-18 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3および腫瘍抗原に結合するヘテロ二量体抗体
|
MX2017006918A
(es)
|
2014-11-26 |
2018-01-25 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cd38.
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
HK1244230A1
(zh)
|
2014-12-03 |
2018-08-03 |
F. Hoffmann-La Roche Ag |
抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
KR20170086536A
(ko)
|
2014-12-03 |
2017-07-26 |
제넨테크, 인크. |
항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
|
PT3227336T
(pt)
|
2014-12-05 |
2019-09-09 |
Hoffmann La Roche |
Anticorpos anti-cd79b e métodos de utilização
|
CN107405398A
(zh)
|
2014-12-05 |
2017-11-28 |
伊穆奈克斯特股份有限公司 |
鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Axlに対するヒトモノクローナル抗体
|
CN107207591A
(zh)
|
2014-12-10 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
血脑屏障受体抗体及使用方法
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
ES3003873T3
(en)
|
2014-12-12 |
2025-03-11 |
Univ Copenhagen |
N-glycosylation
|
MY181199A
(en)
|
2014-12-19 |
2020-12-21 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
CA2971542A1
(en)
|
2014-12-19 |
2016-06-23 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
AR103162A1
(es)
|
2014-12-19 |
2017-04-19 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y métodos para su uso
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
PE20171244A1
(es)
|
2014-12-23 |
2017-08-24 |
Bristol Myers Squibb Co |
Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmunorreceptor (tigit)
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
JP2018511557A
(ja)
|
2015-01-22 |
2018-04-26 |
中外製薬株式会社 |
2種以上の抗c5抗体の組み合わせおよび使用方法
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
JP2018510842A
(ja)
|
2015-02-05 |
2018-04-19 |
中外製薬株式会社 |
イオン濃度依存的抗原結合ドメインを含む抗体、Fc領域改変体、IL−8に結合する抗体、およびその使用
|
WO2016130539A2
(en)
|
2015-02-09 |
2016-08-18 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
HUE061084T2
(hu)
|
2015-02-19 |
2023-05-28 |
Compugen Ltd |
PVRIG elleni antitestek és alkalmazási eljárások
|
EP3978929A1
(en)
|
2015-02-19 |
2022-04-06 |
Compugen Ltd. |
Pvrig polypeptides and methods of treatment
|
WO2016138160A1
(en)
|
2015-02-24 |
2016-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
HK1247287A1
(zh)
|
2015-03-16 |
2018-09-21 |
F. Hoffmann-La Roche Ag |
检测和定量il-13的方法和在诊断和治疗th2相关疾病中的用途
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
HRP20200583T1
(hr)
|
2015-03-20 |
2020-07-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Protutijela koja neutraliziraju gp120 i njihova upotreba
|
CA2978185A1
(en)
|
2015-03-23 |
2016-09-29 |
Stephen Sazinsky |
Antibodies to icos
|
US20160280767A1
(en)
|
2015-03-23 |
2016-09-29 |
Lonza Ltd. |
Methods for controlling protein glycosylation
|
WO2016153572A1
(en)
|
2015-03-25 |
2016-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific multivalent fusion proteins
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
FR3034420A1
(fr)
|
2015-03-31 |
2016-10-07 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-cd303
|
CN107683291B
(zh)
|
2015-04-02 |
2021-11-19 |
英特维特国际股份有限公司 |
针对犬白介素-4受体α的抗体
|
CN107106671B
(zh)
|
2015-04-03 |
2022-01-14 |
优瑞科生物技术公司 |
靶向afp肽/mhc复合体的构建体及其用途
|
SI3286315T1
(sl)
|
2015-04-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
|
HUE047146T2
(hu)
|
2015-04-28 |
2020-04-28 |
Mitsubishi Tanabe Pharma Corp |
RGMa-kötõ fehérje és alkalmazása
|
HK1250997A1
(zh)
|
2015-05-01 |
2019-01-18 |
基因泰克公司 |
掩蔽抗cd3抗體和使用方法
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
CN108137686B
(zh)
|
2015-05-07 |
2022-06-17 |
阿吉纳斯公司 |
抗ox40抗体及其使用方法
|
EP4238994A3
(en)
|
2015-05-11 |
2024-02-07 |
F. Hoffmann-La Roche AG |
Compositions and methods of treating lupus nephritis
|
KR20180008449A
(ko)
|
2015-05-12 |
2018-01-24 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
JP6587696B2
(ja)
*
|
2015-05-13 |
2019-10-09 |
ズムトール バイオロジクス、インコーポレイテッド |
アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
|
JP6770533B2
(ja)
|
2015-05-22 |
2020-10-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Cath−Dの触媒活性と、そのLRP1レセプターへの結合との両方を阻害するヒトモノクローナル抗体フラグメント
|
SI3303396T1
(sl)
|
2015-05-29 |
2023-01-31 |
Bristol-Myers Squibb Company |
Protitelesa proti OX40 in njihova uporaba
|
WO2016196343A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
PL3303395T3
(pl)
|
2015-05-29 |
2020-05-18 |
Abbvie Inc. |
Przeciwciała anty-cd40 i ich zastosowania
|
AU2016271142A1
(en)
|
2015-05-29 |
2017-11-23 |
Genentech, Inc. |
PD-L1 promoter methylation in cancer
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
JP2018516933A
(ja)
|
2015-06-02 |
2018-06-28 |
ジェネンテック, インコーポレイテッド |
抗il−34抗体を使用して神経学的疾患を治療するための組成物及び方法
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
TWI827405B
(zh)
|
2015-06-05 |
2023-12-21 |
美商建南德克公司 |
抗-tau抗體及使用方法
|
EA201792561A1
(ru)
|
2015-06-05 |
2018-04-30 |
Новартис Аг |
Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
HK1251474A1
(zh)
|
2015-06-08 |
2019-02-01 |
豪夫迈‧罗氏有限公司 |
使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
|
CA2988768A1
(en)
|
2015-06-09 |
2016-12-15 |
Memorial Sloan Kettering Cancer Center |
T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
US10017577B2
(en)
|
2015-06-15 |
2018-07-10 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
EP3310378B1
(en)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1 antibodies and methods of use
|
CN114507289A
(zh)
|
2015-06-16 |
2022-05-17 |
豪夫迈·罗氏有限公司 |
人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
|
AU2016280070B2
(en)
|
2015-06-17 |
2022-09-15 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
|
AU2016280159A1
(en)
|
2015-06-17 |
2017-12-07 |
Genentech, Inc. |
Anti-HER2 antibodies and methods of use
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
US10774145B2
(en)
|
2015-06-17 |
2020-09-15 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
AU2016284871B2
(en)
|
2015-06-23 |
2022-09-29 |
Innate Pharma |
Multispecific NK engager proteins
|
EP3108897A1
(en)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
|
WO2016207717A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
JP7021955B2
(ja)
|
2015-06-24 |
2022-03-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Her2及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
|
EP3313879B1
(en)
|
2015-06-24 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies with tailored affinity
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
CA2990572C
(en)
|
2015-06-29 |
2022-07-26 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
CA3162586A1
(en)
|
2015-06-29 |
2017-01-05 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
FR3038517B1
(fr)
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
EP3971211A1
(en)
|
2015-07-13 |
2022-03-23 |
Compugen Ltd. |
Hide1 compositions and methods
|
US10709697B2
(en)
|
2015-07-16 |
2020-07-14 |
Emory University |
Bis-amines, compositions, and uses related to CXCR4 inhibition
|
WO2017021450A1
(en)
|
2015-08-03 |
2017-02-09 |
Engmab Ag |
Monoclonal antibodies against bcma
|
RU2752530C2
(ru)
|
2015-08-03 |
2021-07-29 |
Новартис Аг |
Способы лечения расстройств, связанных с fgf21
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
WO2017040342A1
(en)
|
2015-08-28 |
2017-03-09 |
Genentech, Inc. |
Anti-hypusine antibodies and uses thereof
|
PL3344654T3
(pl)
|
2015-09-02 |
2021-05-17 |
Immutep S.A.S. |
Przeciwciała anty-lag-3
|
DK3347377T3
(da)
|
2015-09-09 |
2021-05-10 |
Novartis Ag |
Tymisk stromal lymfopoietin (TSLP)-bindende antistoffer og fremgangsmåder til anvendelse af antistofferne
|
AU2016320748B2
(en)
|
2015-09-09 |
2019-05-02 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
JP6266164B2
(ja)
|
2015-09-18 |
2018-01-31 |
中外製薬株式会社 |
Il−8に結合する抗体およびその使用
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ox40抗体及びその診断用途
|
EP3353203A2
(en)
|
2015-09-23 |
2018-08-01 |
H. Hoffnabb-La Roche Ag |
Optimized variants of anti-vegf antibodies
|
CN108289954B
(zh)
|
2015-09-24 |
2022-05-31 |
阿布维特罗有限责任公司 |
Hiv抗体组合物和使用方法
|
CA2999819A1
(en)
|
2015-09-24 |
2017-03-30 |
Daiichi Sankyo Company, Limited |
Anti-garp antibody
|
DK3353210T3
(da)
|
2015-09-25 |
2025-01-06 |
Hoffmann La Roche |
Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
CA2997801A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
KR20240107346A
(ko)
|
2015-10-06 |
2024-07-09 |
제넨테크, 인크. |
다발성 경화증을 치료하기 위한 방법
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
HK1258249A1
(zh)
|
2015-10-22 |
2019-11-08 |
震动疗法股份有限公司 |
用於测定icos表达的基因标志
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
CA3000048A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
LT3368578T
(lt)
|
2015-10-30 |
2021-05-25 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš htra1 ir jų naudojimo būdai
|
TW201730211A
(zh)
|
2015-10-30 |
2017-09-01 |
建南德克公司 |
抗因子d抗體及結合物
|
CN115010805B
(zh)
|
2015-11-03 |
2025-01-28 |
美国政府(由卫生和人类服务部的部长所代表) |
Hiv-1 gp41中和抗体及其用途
|
JP6998869B2
(ja)
|
2015-11-08 |
2022-02-04 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体のスクリーニング方法
|
US10323090B2
(en)
|
2015-11-18 |
2019-06-18 |
Merck Sharp & Dohme Corp. |
PD1 and/or LAG3 binders
|
KR102095140B1
(ko)
|
2015-11-18 |
2020-03-31 |
머크 샤프 앤드 돔 코포레이션 |
Ctla4 결합제
|
US10544222B2
(en)
|
2015-11-18 |
2020-01-28 |
Merck Sharp & Dohme Corp. |
PD1/CTLA4 binders
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
WO2017091580A1
(en)
|
2015-11-23 |
2017-06-01 |
Five Prime Therapeutics, Inc. |
Predicting response to cancer treatment with fgfr2 inhibitors
|
WO2017095875A1
(en)
|
2015-11-30 |
2017-06-08 |
Bristol-Myers Squibb Company |
Anti human ip-10 antibodies and their uses
|
US10144768B2
(en)
|
2015-12-04 |
2018-12-04 |
Novartis Ag |
Antibody cytokine engrafted compositions and methods of use for immunoregulation
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
WO2017097723A2
(en)
|
2015-12-09 |
2017-06-15 |
F. Hoffmann-La Roche Ag |
Treatment method
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
BR112018012352A2
(pt)
|
2015-12-16 |
2018-12-11 |
Merck Sharp & Dohme Corp. |
anticorpos anti-lag3 e fragmentos de ligação ao antígeno
|
JP2019506844A
(ja)
|
2015-12-18 |
2019-03-14 |
ノバルティス アーゲー |
CD32bを標的とする抗体およびその使用方法
|
BR112018011073A2
(pt)
|
2015-12-18 |
2018-11-21 |
Chugai Pharmaceutical Co Ltd |
anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
|
PE20240365A1
(es)
|
2015-12-18 |
2024-03-04 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y metodos de uso
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
DK3402503T3
(da)
|
2016-01-13 |
2020-12-21 |
Acerta Pharma Bv |
Terapeutiske kombinationer af et antifolat og en btk-hæmmer
|
EP3405489A1
(en)
|
2016-01-20 |
2018-11-28 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
TWI738713B
(zh)
|
2016-02-06 |
2021-09-11 |
開曼群島商岸邁生物科技有限公司 |
Fabs串聯免疫球蛋白及其用途
|
WO2017137830A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
BR112018015690A2
(pt)
|
2016-02-17 |
2018-12-26 |
Novartis Ag |
anticorpos tgfbeta 2
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
WO2017148880A1
(en)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Obinutuzumab variants having altered cell death induction
|
CA3016187A1
(en)
|
2016-03-04 |
2017-09-08 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
CA3016765A1
(en)
|
2016-03-15 |
2017-09-21 |
Innate Pharma |
Anti-mica antibodies
|
KR102046235B1
(ko)
|
2016-03-15 |
2019-11-18 |
추가이 세이야쿠 가부시키가이샤 |
Pd-1 축 결합 길항제 및 항-gpc3 항체를 사용하여 암을 치료하는 방법
|
CN114907483B
(zh)
|
2016-03-22 |
2024-07-26 |
国家医疗保健研究所 |
人源化抗claudin-1抗体及其用途
|
CA3018081A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
CN108700598A
(zh)
|
2016-03-25 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
多路总抗体和抗体缀合的药物量化测定法
|
WO2017181034A1
(en)
|
2016-04-14 |
2017-10-19 |
Bristol-Myers Squibb Company |
Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
|
EP3443004A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3 antibodies and methods of use
|
WO2017181111A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
WO2017181139A2
(en)
|
2016-04-15 |
2017-10-19 |
Michael Molloy |
Anti-human vista antibodies and use thereof
|
WO2017181079A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
CA3021086C
(en)
|
2016-04-15 |
2023-10-17 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
EP3445393A4
(en)
|
2016-04-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
CMV NEUTRALIZATION ANTIGEN BINDING PROTEINS
|
EP3448887A1
(en)
|
2016-04-27 |
2019-03-06 |
Novartis AG |
Antibodies against growth differentiation factor 15 and uses thereof
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
MA56474A
(fr)
|
2016-05-02 |
2022-05-11 |
Hoffmann La Roche |
Contorsbody - liant de cible à chaîne unique
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
JP7089483B2
(ja)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
修飾された抗テネイシン抗体及び使用方法
|
MX394735B
(es)
|
2016-05-13 |
2025-03-24 |
Bioatla Llc |
Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
|
EA201892655A1
(ru)
|
2016-05-18 |
2019-04-30 |
Генмаб Б.В. |
Антитела и способы их применения при лечении инфекционной болезни
|
ES2858151T3
(es)
|
2016-05-20 |
2021-09-29 |
Hoffmann La Roche |
Conjugados de PROTAC-anticuerpo y procedimientos de uso
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
AU2017277914A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-CD98 antibodies and antibody drug conjugates
|
US20190153108A1
(en)
|
2016-06-08 |
2019-05-23 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
JP7148504B2
(ja)
|
2016-06-08 |
2022-10-05 |
ゼンコー,インコーポレイティド |
CD32Bに交差結合した抗CD19抗体を用いたIgG4関連疾患の治療
|
MX2018015284A
(es)
|
2016-06-08 |
2019-09-18 |
Abbvie Inc |
Conjugados de anticuerpo anti-egfr y fármaco.
|
EP3469000A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
EP4104865A1
(en)
|
2016-06-08 |
2022-12-21 |
AbbVie Inc. |
Anti-egfr antibody drug conjugates
|
CN109562168A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
WO2017214322A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CA3027045A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CN109562170B
(zh)
|
2016-06-08 |
2023-01-13 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
EP3468586B1
(en)
|
2016-06-14 |
2024-08-07 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
EP3471759A1
(en)
|
2016-06-15 |
2019-04-24 |
Novartis AG |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
|
SG11201705585QA
(en)
|
2016-06-17 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies and methods of use
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
EP3475298A1
(en)
|
2016-06-24 |
2019-05-01 |
H. Hoffnabb-La Roche Ag |
Anti-polyubiquitin multispecific antibodies
|
EP3475304B1
(en)
|
2016-06-28 |
2022-03-23 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
JP7027401B2
(ja)
|
2016-07-14 |
2022-03-01 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tim3に対する抗体およびその使用
|
CA3030834A1
(en)
|
2016-07-15 |
2018-01-18 |
Takeda Pharmaceutical Company Limited |
Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EP3490676A1
(en)
|
2016-07-29 |
2019-06-05 |
Eli Lilly and Company |
Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
|
BR112019001693A2
(pt)
|
2016-07-29 |
2019-07-02 |
Ct Hospitalier Universitaire Toulouse |
anticorpos direcionados a macrófagos associados a tumores e seus usos
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
BR112019001327A2
(pt)
|
2016-07-29 |
2019-04-30 |
Juno Therapeutics Inc |
anticorpos anti-idiotípicos e métodos relacionados
|
BR112019001179A2
(pt)
|
2016-07-29 |
2019-04-30 |
Chugai Seiyaku Kabushiki Kaisha |
anticorpo biespecífico que exibe atividade alternativa aumentada de função de cofator fviii
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
US11649285B2
(en)
|
2016-08-03 |
2023-05-16 |
Bio-Techne Corporation |
Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
|
IL264626B
(en)
|
2016-08-05 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Composition for prophylaxis or treatment of il-8 related diseases
|
US11773162B2
(en)
|
2016-08-05 |
2023-10-03 |
Allakos, Inc. |
Anti-Siglec-7 antibodies for the treatment of cancer
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
ES2963385T3
(es)
|
2016-08-16 |
2024-03-26 |
Epimab Biotherapeutics Inc |
Anticuerpos biespecíficos Fab en tándem asimétricos monovalentes
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
WO2018049083A1
(en)
|
2016-09-07 |
2018-03-15 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
EP3512883A1
(en)
|
2016-09-13 |
2019-07-24 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of pulmonary fibrosis
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
EP3515932B1
(en)
|
2016-09-19 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Complement factor based affinity chromatography
|
IL265473B2
(en)
|
2016-09-23 |
2024-01-01 |
Genentech Inc |
Uses of IL-13 antagonists for the treatment of atopic dermatitis
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
AU2017338827B2
(en)
|
2016-10-03 |
2023-08-31 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
MX2019003934A
(es)
|
2016-10-06 |
2019-07-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
US20190330368A1
(en)
|
2016-10-07 |
2019-10-31 |
Daiichi Sankyo Company, Limited |
Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
AU2017343778A1
(en)
|
2016-10-13 |
2019-05-02 |
Massachusetts Institute Of Technology |
Antibodies that bind Zika virus envelope protein and uses thereof
|
EP3526240A1
(en)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
JP7676109B2
(ja)
|
2016-10-21 |
2025-05-14 |
イナート・ファルマ・ソシエテ・アノニム |
抗kir3dl2剤による処置
|
AU2017351764A1
(en)
|
2016-10-25 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Monoclonal antibodies binding to the CD160 transmembrane isoform
|
AU2017348734B2
(en)
|
2016-10-28 |
2024-09-26 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
US20190263926A1
(en)
|
2016-10-28 |
2019-08-29 |
Astute Medical, Inc. |
Use of Antibodies to TIMP-2 for the Improvement of Renal Function
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
KR20190070977A
(ko)
|
2016-11-01 |
2019-06-21 |
젠맵 비. 브이 |
폴리펩티드 변이체 및 그의 용도
|
WO2018083204A1
(en)
|
2016-11-02 |
2018-05-11 |
Engmab Sàrl |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
HUE057559T2
(hu)
|
2016-11-02 |
2022-06-28 |
Jounce Therapeutics Inc |
PD-1 elleni antitestek és alkalmazásaik
|
EA201990875A1
(ru)
|
2016-11-03 |
2019-09-30 |
Бристол-Маерс Сквибб Компани |
Активируемые антитела против ctla-4 и их применение
|
EP3538546B1
(en)
|
2016-11-14 |
2025-01-08 |
Novartis AG |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
KR20190074300A
(ko)
|
2016-11-15 |
2019-06-27 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
|
ES2866348T3
(es)
|
2016-11-16 |
2021-10-19 |
Lilly Co Eli |
Terapia de combinación para el cáncer con mutación o mutaciones de omisión del exón 14 o fenotipo de omisión del exón 14
|
EP4015532A1
(en)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73 antibodies and immunoconjugates
|
PE20200012A1
(es)
|
2016-11-23 |
2020-01-06 |
Bioverativ Therapeutics Inc |
Anticuerpos mono- y biespecificos que se unen al factor de coagulacion ix y al factor de coagulacion x
|
EP3544628A4
(en)
|
2016-11-23 |
2020-11-18 |
Immunoah Therapeutics, Inc. |
4-1BB BINDING PROTEINS AND THEIR USES
|
WO2018101448A1
(en)
|
2016-11-30 |
2018-06-07 |
Kyowa Hakko Kirin Co., Ltd. |
Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
|
WO2018102746A1
(en)
|
2016-12-02 |
2018-06-07 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to tigit
|
WO2018106776A2
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
EP3551225A1
(en)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Antibodies and methods of use thereof
|
CN110290801B
(zh)
|
2016-12-07 |
2024-01-26 |
基因泰克公司 |
抗tau抗体和使用方法
|
WO2018111890A1
(en)
|
2016-12-12 |
2018-06-21 |
Genentech, Inc. |
Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
|
TW202508642A
(zh)
|
2016-12-12 |
2025-03-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
|
EP3554544A4
(en)
|
2016-12-16 |
2020-07-29 |
Bluefin Biomedicine, Inc. |
ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
|
SG10201912366YA
(en)
|
2016-12-22 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Anti-cd3 antibody and molecules comprising the antibody
|
CN110325550B
(zh)
|
2016-12-23 |
2024-03-08 |
诺华股份有限公司 |
因子xi抗体和使用方法
|
US20190322767A1
(en)
|
2016-12-23 |
2019-10-24 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
EP3523332B1
(en)
|
2017-01-06 |
2021-12-29 |
Eutilex Co., Ltd. |
Anti-human 4-1 bb antibodies and use thereof
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
MA47236A
(fr)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des agonistes de la superfamille des récepteurs du facteur de nécrose tumorale (tnfrsf) et des combinaisons thérapeutiques de til et d'agonistes de tnfrsf
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
WO2018129533A1
(en)
|
2017-01-09 |
2018-07-12 |
Shuttle Pharmaceuticals, Llc |
Selective histone deacetylase inhibitors for the treatment of human disease
|
WO2018132597A1
(en)
|
2017-01-12 |
2018-07-19 |
Eureka Therapeutics, Inc. |
Constructs targeting histone h3 peptide/mhc complexes and uses thereof
|
WO2018135501A1
(ja)
|
2017-01-17 |
2018-07-26 |
第一三共株式会社 |
抗gpr20抗体及び抗gpr20抗体-薬物コンジュゲート
|
EP3574918A4
(en)
|
2017-01-24 |
2021-03-03 |
Kyowa Kirin Co., Ltd. |
THERAPEUTIC OR PROPHYLACTIC AGENT, AND METHOD OF TREATMENT OR PREVENTION OF ACUTE IRRADIATION SYNDROME
|
SG11201907321TA
(en)
|
2017-02-07 |
2019-09-27 |
Daiichi Sankyo Co Ltd |
Anti-gprc5d antibody and molecule comprising the antibody
|
DK3580237T3
(da)
|
2017-02-08 |
2025-06-30 |
Novartis Ag |
Fgf21-mimetiske antistoffer og anvendelser deraf
|
MA47459A
(fr)
|
2017-02-10 |
2019-12-18 |
Hoffmann La Roche |
Anticorps anti-tryptase, compositions les contenant et leurs utilisations
|
AU2018218345B2
(en)
|
2017-02-10 |
2025-04-03 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
WO2018146253A1
(en)
|
2017-02-10 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
EP3882271A3
(en)
|
2017-02-10 |
2022-01-05 |
Eutilex Co., Ltd. |
Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
|
US11021535B2
(en)
|
2017-02-10 |
2021-06-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
EP3583124A1
(en)
|
2017-02-17 |
2019-12-25 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
SG11201907050PA
(en)
|
2017-02-28 |
2019-09-27 |
Univ Kinki |
Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
|
BR112019017695A2
(pt)
|
2017-02-28 |
2020-04-07 |
Bristol-Myers Squibb Company |
uso de anticorpos anti-ctla-4 com adcc acentuada para acentuar a resposta imune a uma vacina
|
CA3052670A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
EP3589654A1
(en)
|
2017-03-02 |
2020-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
WO2018159845A1
(ja)
|
2017-03-02 |
2018-09-07 |
学校法人 聖マリアンナ医科大学 |
低用量抗ccr4抗体を用いたhtlv-1関連脊髄症の予防または治療剤
|
TWI839327B
(zh)
|
2017-03-22 |
2024-04-21 |
美商建南德克公司 |
用於治療眼部病症之最佳化之抗體組合物
|
CN119971025A
(zh)
|
2017-03-24 |
2025-05-13 |
诺华股份有限公司 |
用于预防和治疗心脏病的方法
|
JP2020515543A
(ja)
|
2017-03-28 |
2020-05-28 |
ジェネンテック, インコーポレイテッド |
神経変性疾患の治療方法
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
TWI796329B
(zh)
|
2017-04-07 |
2023-03-21 |
美商默沙東有限責任公司 |
抗-ilt4抗體及抗原結合片段
|
SG11201908813QA
(en)
|
2017-04-13 |
2019-10-30 |
Aduro Biotech Holdings Europe B V |
Anti-sirp alpha antibodies
|
KR20200005540A
(ko)
|
2017-04-14 |
2020-01-15 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
EP3612567B1
(en)
|
2017-04-19 |
2024-09-11 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
US20190078160A1
(en)
|
2017-04-21 |
2019-03-14 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
KR20240067275A
(ko)
|
2017-04-26 |
2024-05-16 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
CN110799541A
(zh)
|
2017-04-27 |
2020-02-14 |
特沙诺有限公司 |
针对淋巴细胞活化基因-3(lag-3)的抗体药剂及其用途
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
EA201992626A1
(ru)
|
2017-05-05 |
2020-04-24 |
Аллакос Инк. |
Способы и композиции для лечения аллергических заболеваний глаз
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
US11116835B2
(en)
|
2017-05-10 |
2021-09-14 |
Fred Hutchinson Cancer Research Center |
Epstein Barr virus antibodies, vaccines, and uses of the same
|
TW202504644A
(zh)
|
2017-05-15 |
2025-02-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之用途
|
WO2018213097A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
BR112019023898A2
(pt)
|
2017-05-16 |
2020-06-09 |
Five Prime Therapeutics Inc |
método para tratamento de câncer gástrico, uso de um anticorpo e composição
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
CN110662762A
(zh)
|
2017-05-24 |
2020-01-07 |
诺华股份有限公司 |
抗体细胞因子移植蛋白和用于治疗癌症的方法
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
BR112019024419A2
(pt)
|
2017-05-25 |
2020-07-14 |
Bristol-Myers Squibb Company |
anticorpos compreendendo regiões constantes pesadas modificadas
|
JP7678493B2
(ja)
|
2017-05-29 |
2025-05-16 |
エクセリクシス, インク. |
癌関連免疫抑制阻害剤
|
MX2019014265A
(es)
|
2017-06-01 |
2020-08-03 |
Compugen Ltd |
Tratamientos conjuntos triples con anticuerpos.
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
CN118994394A
(zh)
|
2017-06-12 |
2024-11-22 |
蓝鳍生物医药公司 |
抗-il1rap抗体和抗体药物缀合物
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
AU2018301393B2
(en)
|
2017-07-11 |
2025-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
CN110959014B
(zh)
|
2017-07-18 |
2024-01-16 |
协和麒麟株式会社 |
抗人ccr1单克隆抗体
|
EP3655034A1
(en)
|
2017-07-21 |
2020-05-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
PL3658589T3
(pl)
|
2017-07-26 |
2024-03-18 |
Forty Seven, Inc. |
Przeciwciała anty-sirp-alfa i powiązane sposoby
|
US11661451B2
(en)
|
2017-07-27 |
2023-05-30 |
Daiichi Sankyo Company, Limited |
Anti-CD147 antibody
|
WO2019039483A1
(ja)
|
2017-08-23 |
2019-02-28 |
第一三共株式会社 |
抗体-薬物コンジュゲートの製剤及びその凍結乾燥方法
|
CN119552248A
(zh)
|
2017-08-25 |
2025-03-04 |
戊瑞治疗有限公司 |
B7-h4抗体及其使用方法
|
KR102816741B1
(ko)
|
2017-08-31 |
2025-06-04 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 개량 제조 방법
|
JP7248578B2
(ja)
|
2017-08-31 |
2023-03-29 |
第一三共株式会社 |
抗体-薬物コンジュゲートの新規製造方法
|
EP4512469A3
(en)
|
2017-09-11 |
2025-05-21 |
Monash University |
Binding proteins to the human thrombin receptor, par4
|
JP7382922B2
(ja)
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン
|
MX2020003125A
(es)
|
2017-09-29 |
2020-10-01 |
Daiichi Sankyo Co Ltd |
Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
BR112020006860A2
(pt)
|
2017-10-05 |
2020-10-20 |
Daiichi Sankyo Company, Limited |
composição para depleção de células t citotóxicas
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
US11912754B2
(en)
|
2017-10-12 |
2024-02-27 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
PL3707510T3
(pl)
|
2017-11-06 |
2024-09-30 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
|
CA3082383A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
CN111344307B
(zh)
|
2017-11-08 |
2025-01-14 |
协和麒麟株式会社 |
与CD40和EpCAM结合的双特异性抗体
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
EP3713959A1
(en)
|
2017-11-21 |
2020-09-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
CA3083118A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
US20200308301A1
(en)
|
2017-11-22 |
2020-10-01 |
Novartis Ag |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
MX2020005662A
(es)
|
2017-12-01 |
2020-08-20 |
Pfizer |
Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
|
EP3717508A1
(en)
|
2017-12-01 |
2020-10-07 |
The University of Copenhagen |
Peptide hormone with one or more o-glycans
|
US11433132B2
(en)
|
2017-12-01 |
2022-09-06 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
CA3085765A1
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
EA202091540A1
(ru)
|
2017-12-22 |
2021-03-22 |
Джаунс Терапьютикс, Инк. |
Антитела к lilrb2
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
CN115925943A
(zh)
|
2017-12-27 |
2023-04-07 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
AU2018396964C1
(en)
|
2017-12-28 |
2024-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against PD-L1
|
EP3732202A4
(en)
|
2017-12-28 |
2022-06-15 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
|
CN112041341B
(zh)
|
2017-12-28 |
2024-05-24 |
机敏医药股份有限公司 |
Ccl14的抗体和检测
|
EP3724223A1
(en)
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
JP7653013B2
(ja)
|
2018-01-04 |
2025-03-28 |
アイコニック セラピューティクス リミテッド ライアビリティ カンパニー |
抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
|
CA3086879A1
(en)
|
2018-01-05 |
2019-07-11 |
Ac Immune Sa |
Misfolded tdp-43 binding molecules
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US12129297B2
(en)
|
2018-01-12 |
2024-10-29 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
KR102839330B1
(ko)
|
2018-01-15 |
2025-07-30 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-1에 대한 단일-도메인 항체 및 이의 변이체
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
TWI835773B
(zh)
|
2018-01-26 |
2024-03-21 |
美商建南德克公司 |
組合物及使用方法
|
SG11202006259SA
(en)
|
2018-01-26 |
2020-08-28 |
Genentech Inc |
Il-22 fc fusion proteins and methods of use
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
AU2019214183B2
(en)
|
2018-02-01 |
2022-04-07 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
|
EP3746477A1
(en)
|
2018-02-02 |
2020-12-09 |
Bio-Techne Corporation |
Compounds that modulate the interaction of vista and vsig3 and methods of making and using
|
MA51793A
(fr)
|
2018-02-08 |
2020-12-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
|
CN111787947A
(zh)
|
2018-02-09 |
2020-10-16 |
豪夫迈·罗氏有限公司 |
用于肥大细胞介导的炎性疾病的治疗和诊断方法
|
EP3752600A1
(en)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
WO2019158645A1
(en)
|
2018-02-14 |
2019-08-22 |
Abba Therapeutics Ag |
Anti-human pd-l2 antibodies
|
SG11202007820QA
(en)
|
2018-02-21 |
2020-09-29 |
Five Prime Therapeutics Inc |
B7-h4 antibody dosing regimens
|
US11760790B2
(en)
|
2018-02-21 |
2023-09-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to HIV-1 Env and their use
|
MX2020008736A
(es)
|
2018-02-21 |
2020-12-07 |
Five Prime Therapeutics Inc |
Formulaciones de anticuerpos b7-h4.
|
MX2020008502A
(es)
|
2018-02-21 |
2020-09-25 |
Genentech Inc |
Dosis para el tratamiento con proteinas de fusion il-22 fc.
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
EA202091810A1
(ru)
|
2018-03-02 |
2021-01-29 |
Файв Прайм Терапьютикс, Инк. |
Антитела к b7-h4 и способы их применения
|
AU2019231380A1
(en)
|
2018-03-05 |
2020-09-24 |
Daiichi Sankyo Company, Limited |
Pharmaceutical composition for treating or preventing heterotopic ossification
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
TW202003562A
(zh)
|
2018-03-14 |
2020-01-16 |
中國大陸商北京軒義醫藥科技有限公司 |
抗密連蛋白18.2(cldn18.2)抗體
|
CN112119090B
(zh)
|
2018-03-15 |
2023-01-13 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
TW201945393A
(zh)
|
2018-03-21 |
2019-12-01 |
美商戊瑞治療有限公司 |
在酸性pH結合至VISTA之抗體
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
AU2019242520A1
(en)
|
2018-03-30 |
2020-10-29 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
KR20200138720A
(ko)
|
2018-03-30 |
2020-12-10 |
난징 레전드 바이오테크 씨오., 엘티디. |
Lag-3에 대한 단일-도메인 항체 및 이의 용도
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
KR102764123B1
(ko)
|
2018-04-05 |
2025-02-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Τ 세포 수용체 및 이를 발현하는 조작된 세포
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
KR20210010862A
(ko)
|
2018-04-18 |
2021-01-28 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
AU2019264217A1
(en)
|
2018-05-03 |
2020-12-17 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
CA3096703A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
EP3788079A4
(en)
|
2018-05-03 |
2022-12-21 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
|
EP3794023A1
(en)
|
2018-05-14 |
2021-03-24 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
EP3794024B1
(en)
|
2018-05-14 |
2023-05-10 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
JP7257422B2
(ja)
|
2018-05-18 |
2023-04-13 |
第一三共株式会社 |
抗muc1抗体-薬物コンジュゲート
|
JP2021525243A
(ja)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Nk細胞による標的細胞の殺傷を増進するための組成物および方法
|
IL278988B2
(en)
|
2018-05-28 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
Anti-her2 antibody-drug conjugates for use in the treatment of her-2 mutated cancer
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
EP3801766A1
(en)
|
2018-05-31 |
2021-04-14 |
Novartis AG |
Hepatitis b antibodies
|
KR102729319B1
(ko)
|
2018-05-31 |
2024-11-11 |
다이이찌 산쿄 가부시키가이샤 |
항인간 tlr7 항체
|
CN112533952B
(zh)
|
2018-06-01 |
2023-03-07 |
大有华夏生物医药集团有限公司 |
治疗疾病或病况的组合物及其用途
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
SG11202010579XA
(en)
|
2018-06-01 |
2020-12-30 |
Novartis Ag |
Binding molecules against bcma and uses thereof
|
CA3102398A1
(en)
|
2018-06-03 |
2019-12-12 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against ceacam5 and cd47
|
US20210238308A1
(en)
|
2018-06-04 |
2021-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule showing changed half-life in cytoplasm
|
TW202519270A
(zh)
|
2018-06-07 |
2025-05-16 |
美商思進公司 |
喜樹鹼結合物
|
US11993661B2
(en)
|
2018-06-18 |
2024-05-28 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020004490A1
(ja)
|
2018-06-26 |
2020-01-02 |
協和キリン株式会社 |
コンドロイチン硫酸プロテオグリカン-5に結合する抗体
|
JP7397445B2
(ja)
|
2018-06-26 |
2023-12-13 |
協和キリン株式会社 |
Cell Adhesion Molecule3に結合する抗体
|
MA53094A
(fr)
|
2018-07-02 |
2021-05-12 |
Amgen Inc |
Protéine de liaison à l'antigène anti-steap1
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
PE20211604A1
(es)
|
2018-07-09 |
2021-08-23 |
Five Prime Therapeutics Inc |
Anticuerpos de union a ilt4
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
PE20210687A1
(es)
|
2018-07-11 |
2021-04-08 |
Bristol Myers Squibb Co |
Anticuerpos de union a vista a ph acido
|
WO2020012038A1
(en)
|
2018-07-13 |
2020-01-16 |
Genmab A/S |
Trogocytosis-mediated therapy using cd38 antibodies
|
TW202019518A
(zh)
|
2018-07-13 |
2020-06-01 |
丹麥商珍美寶股份有限公司 |
Cd38抗體之變體及其用途
|
JP2021530502A
(ja)
|
2018-07-18 |
2021-11-11 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
|
EP3823673A4
(en)
|
2018-07-20 |
2022-05-11 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
AU2019311557A1
(en)
|
2018-07-25 |
2021-02-04 |
Daiichi Sankyo Company, Limited |
Effective method for manufacturing antibody-drug conjugate
|
WO2020027100A1
(ja)
|
2018-07-31 |
2020-02-06 |
第一三共株式会社 |
抗体-薬物コンジュゲート投与による転移性脳腫瘍の治療
|
EP3831854A4
(en)
|
2018-08-03 |
2022-05-04 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING TWO ANTIGEN-BINDING DOMAINS LINKED TO EACH OTHER
|
EP3834843A4
(en)
|
2018-08-06 |
2022-05-11 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and tubulin inhibitor
|
US12172106B2
(en)
|
2018-08-09 |
2024-12-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptor
|
UA128584C2
(uk)
|
2018-08-10 |
2024-08-21 |
Чугаі Сейяку Кабусікі Кайся |
Антигензв'язувальна молекула проти cd137 та її застосування
|
US12259395B2
(en)
|
2018-08-17 |
2025-03-25 |
Ab Studio Inc. |
Catabodies and methods of use thereof
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
WO2020040245A1
(ja)
|
2018-08-23 |
2020-02-27 |
第一三共株式会社 |
抗体薬物複合体の感受性マーカー
|
EP3841123A2
(en)
|
2018-08-23 |
2021-06-30 |
Seagen Inc. |
Anti-tigit antibodies
|
PL3844189T3
(pl)
|
2018-08-31 |
2025-03-31 |
Regeneron Pharmaceuticals, Inc. |
Strategia dawkowania, która łagodzi zespół uwalniania cytokin, dla przeciwciał dwuswoistych cd3/cd20
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
CA3110750A1
(en)
|
2018-09-10 |
2020-03-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against cd33 and constructs thereof
|
US12398402B2
(en)
|
2018-09-12 |
2025-08-26 |
Fred Hutchinson Cancer Center |
Reducing CD33 expression to selectively protect therapeutic cells
|
EP3849608B1
(en)
|
2018-09-13 |
2023-08-30 |
The Board of Regents of The University of Texas System |
Novel lilrb4 antibodies and uses thereof
|
CN113396160A
(zh)
|
2018-09-19 |
2021-09-14 |
国家医疗保健研究所 |
治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
|
KR20210063330A
(ko)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
방광암에 대한 치료 및 진단 방법
|
MX2021002887A
(es)
|
2018-09-20 |
2021-06-04 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores (tils) a partir de muestras de tumor crioconservadas.
|
EP3854418A4
(en)
|
2018-09-20 |
2022-07-27 |
Daiichi Sankyo Company, Limited |
Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate
|
EP3857230B1
(en)
|
2018-09-21 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
CA3112989A1
(en)
|
2018-09-27 |
2020-04-02 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
US20210380684A1
(en)
|
2018-09-28 |
2021-12-09 |
Kyowa Kirin Co., Ltd. |
Antibody composition
|
MA53822A
(fr)
|
2018-10-03 |
2021-08-11 |
Xencor Inc |
Protéines de fusion fc hétérodimères d'il -12
|
AU2019355995A1
(en)
|
2018-10-05 |
2021-04-08 |
Five Prime Therapeutics, Inc. |
Anti-FGFR2 antibody formulations
|
TW202035445A
(zh)
|
2018-10-10 |
2020-10-01 |
美商帝洛斯療法股份有限公司 |
抗lap抗體變異體及其用途
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
MA53911A
(fr)
|
2018-10-15 |
2022-01-19 |
Five Prime Therapeutics Inc |
Polythérapie contre le cancer
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
CN113196061A
(zh)
|
2018-10-18 |
2021-07-30 |
豪夫迈·罗氏有限公司 |
肉瘤样肾癌的诊断和治疗方法
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
TW202039831A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
對抗pd-1抗體呈現難治性之非小細胞肺癌(nsclc)病患之治療
|
CA3118493A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
WO2020094609A1
(en)
|
2018-11-06 |
2020-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
KR20210107628A
(ko)
|
2018-11-13 |
2021-09-01 |
콤파스 테라퓨틱스 엘엘씨 |
체크포인트 분자에 대한 다중특이적 결합 작제물 및 이의 용도
|
TW202031298A
(zh)
|
2018-11-14 |
2020-09-01 |
日商第一三共股份有限公司 |
抗cdh6抗體-吡咯并苯二氮呯衍生物結合物
|
CA3119968A1
(en)
|
2018-11-16 |
2020-05-22 |
Memorial Sloan Kettering Cancer Center |
Antibodies to mucin-16 and methods of use thereof
|
WO2020112781A1
(en)
|
2018-11-28 |
2020-06-04 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
KR20210100656A
(ko)
|
2018-12-05 |
2021-08-17 |
제넨테크, 인크. |
암 면역요법을 위한 진단 방법 및 조성물
|
WO2020117257A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
JP2022513198A
(ja)
|
2018-12-10 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
|
KR20210102341A
(ko)
|
2018-12-11 |
2021-08-19 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 parp 저해제의 조합
|
JP7609775B2
(ja)
|
2018-12-14 |
2025-01-07 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
単離されたMHC由来ヒトペプチドおよびCD8+CD45RClowTregの抑制機能を刺激し、かつ活性化するためのその使用
|
WO2020128863A1
(en)
|
2018-12-19 |
2020-06-25 |
Novartis Ag |
Anti-tnf-alpha antibodies
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
EP3898667A2
(en)
|
2018-12-20 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Modified antibody fcs and methods of use
|
US20220089694A1
(en)
|
2018-12-20 |
2022-03-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
EA202191656A1
(ru)
|
2018-12-21 |
2021-10-26 |
23Эндми, Инк. |
Анти-il-36 антитела и способы их применения
|
KR20210107069A
(ko)
|
2018-12-21 |
2021-08-31 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 키나아제 저해제의 조합
|
KR20210142594A
(ko)
|
2018-12-26 |
2021-11-25 |
시티 오브 호프 |
활성화 가능한 차폐된 항-ctla4 결합 단백질
|
MX2021007797A
(es)
|
2018-12-28 |
2021-10-26 |
Kyowa Kirin Co Ltd |
Anticuerpo biespecifico que se une al receptor de transferrina (tfr).
|
WO2020141145A1
(en)
|
2018-12-30 |
2020-07-09 |
F. Hoffmann-La Roche Ag |
Anti-rabbit cd19 antibodies and methods of use
|
EP3908678A1
(en)
|
2019-01-10 |
2021-11-17 |
Iovance Biotherapeutics, Inc. |
System and methods for monitoring adoptive cell therapy clonality and persistence
|
WO2020150152A1
(en)
|
2019-01-14 |
2020-07-23 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
CN109762067B
(zh)
|
2019-01-17 |
2020-02-28 |
北京天广实生物技术股份有限公司 |
结合人Claudin 18.2的抗体及其用途
|
JP7285936B2
(ja)
|
2019-01-22 |
2023-06-02 |
ブリストル-マイヤーズ スクイブ カンパニー |
Il-7rアルファサブユニットに対する抗体及びその使用
|
JP2022523047A
(ja)
|
2019-01-23 |
2022-04-21 |
エンセファ |
Cd31競合剤およびその使用
|
WO2020151572A1
(en)
|
2019-01-23 |
2020-07-30 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-pd-l1 diabodies and the use thereof
|
JPWO2020153467A1
(ja)
|
2019-01-24 |
2021-12-02 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
BR112021014833A2
(pt)
|
2019-01-29 |
2021-10-05 |
Juno Therapeutics, Inc. |
Anticorpos e receptores antigênicos quiméricos específicos para receptor órfão 1 de tipo tirosina quinase de receptor (ror1)
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
KR20210133237A
(ko)
|
2019-02-27 |
2021-11-05 |
제넨테크, 인크. |
항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
|
EP3931310A1
(en)
|
2019-03-01 |
2022-01-05 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
BR112021016955A2
(pt)
|
2019-03-01 |
2021-11-23 |
Xencor Inc |
Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
|
WO2020185535A1
(en)
|
2019-03-08 |
2020-09-17 |
Genentech, Inc. |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
US20220177581A1
(en)
|
2019-03-11 |
2022-06-09 |
Memorial Sloan Kettering Cancer Center |
Cd22 antibodies and methods of using the same
|
SG11202109424RA
(en)
|
2019-03-14 |
2021-09-29 |
Genentech Inc |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
EP3943108A4
(en)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
|
BR112021017616A2
(pt)
|
2019-03-25 |
2021-11-09 |
Daiichi Sankyo Co Ltd |
Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
|
TWI856078B
(zh)
|
2019-03-25 |
2024-09-21 |
日商第一三共股份有限公司 |
抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
|
BR112021017350A2
(pt)
|
2019-03-27 |
2021-11-16 |
Daiichi Sankyo Co Ltd |
Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
|
US20220169706A1
(en)
|
2019-03-28 |
2022-06-02 |
Danisco Us Inc |
Engineered antibodies
|
EP3955960B1
(en)
|
2019-04-18 |
2025-01-15 |
Bristol-Myers Squibb Company |
Ipilimumab variants with enhanced specificity for binding at low ph
|
WO2020213724A1
(ja)
|
2019-04-19 |
2020-10-22 |
中外製薬株式会社 |
抗体改変部位認識キメラ受容体
|
JP7593939B2
(ja)
|
2019-04-19 |
2024-12-03 |
ジェネンテック, インコーポレイテッド |
抗mertk抗体及びその使用方法
|
KR20220004744A
(ko)
|
2019-05-03 |
2022-01-11 |
제넨테크, 인크. |
항-pd-l1 항체를 이용하여 암을 치료하는 방법
|
US12269872B2
(en)
|
2019-05-03 |
2025-04-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to Plasmodium falciparum circumsporozoite protein and their use
|
SG11202112541RA
(en)
|
2019-05-14 |
2021-12-30 |
Werewolf Therapeutics Inc |
Separation moieties and methods and use thereof
|
BR112021022815A2
(pt)
|
2019-05-14 |
2021-12-28 |
Genentech Inc |
Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
|
JP7502281B2
(ja)
|
2019-05-15 |
2024-06-18 |
協和キリン株式会社 |
Cd40とgpc3に結合するバイスペシフィック抗体
|
CN113891728A
(zh)
|
2019-05-15 |
2022-01-04 |
协和麒麟株式会社 |
与cd40和fap结合的双特异性抗体
|
US20230091510A1
(en)
|
2019-05-20 |
2023-03-23 |
Novartis Ag |
Antibody drug conjugates having linkers comprising hydrophilic groups
|
CN114630838A
(zh)
|
2019-05-20 |
2022-06-14 |
法国国家健康和医学研究院 |
新的抗cd25抗体
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
PH12021552916A1
(en)
|
2019-05-21 |
2022-04-04 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
EP3972634A2
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Trispecific binding molecules against bcma and uses thereof
|
WO2020234473A1
(en)
|
2019-05-23 |
2020-11-26 |
Ac Immune Sa |
Anti-tdp-43 binding molecules and uses thereof
|
TW202108180A
(zh)
|
2019-05-29 |
2021-03-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物的調劑
|
BR112021024938A2
(pt)
|
2019-06-12 |
2022-01-25 |
Novartis Ag |
Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
|
JP2022539178A
(ja)
|
2019-06-26 |
2022-09-07 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Il1rap結合タンパク質
|
EA202290208A1
(ru)
|
2019-07-02 |
2022-03-25 |
Дзе Юнайтед Стейтс Оф Эмерика, Эз Репрезентед Бай Дзе Секретэри, Дипартмент Оф Хелт Энд Хьюман Сервисиз |
МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ
|
EP3998083A4
(en)
|
2019-07-12 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREOF
|
US20220251208A1
(en)
|
2019-07-15 |
2022-08-11 |
Intervet Inc. |
Caninized Antibodies Against Canine CTLA-4
|
US20220251209A1
(en)
|
2019-07-15 |
2022-08-11 |
Intervet Inc. |
Caninized antibodies to human ctla-4
|
JP2022541200A
(ja)
|
2019-07-16 |
2022-09-22 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
Cd38に特異性を有する抗体及びその使用
|
JP2022542863A
(ja)
|
2019-07-24 |
2022-10-07 |
ハー・ルンドベック・アクチエゼルスカベット |
抗mGluR5抗体及びその使用
|
EP4008350A4
(en)
|
2019-07-26 |
2023-06-14 |
Saitama Medical University |
ANTIBODIES RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1
|
AU2020323926A1
(en)
|
2019-07-29 |
2022-03-10 |
Compugen Ltd. |
Anti-PVRIG antibodies formulations and uses thereof
|
AU2020325770B2
(en)
|
2019-08-06 |
2022-08-25 |
Aprinoia Therapeutics Limited |
Antibodies that bind to pathological tau species and uses thereof
|
KR20220041915A
(ko)
|
2019-08-06 |
2022-04-01 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
바이오제약 조성물 및 관련 방법
|
WO2021050645A1
(en)
|
2019-09-12 |
2021-03-18 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
WO2021055694A1
(en)
|
2019-09-20 |
2021-03-25 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
KR20220070237A
(ko)
|
2019-09-27 |
2022-05-30 |
제넨테크, 인크. |
항-tigit 및 항-pd-l1 길항제 항체를 이용한 치료를 위한 투약
|
TW202126688A
(zh)
|
2019-09-27 |
2021-07-16 |
瑞典商阿斯特捷利康公司 |
使用貝那利珠單抗治療遲發性氣喘之方法
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
TW202122114A
(zh)
|
2019-10-18 |
2021-06-16 |
美商建南德克公司 |
使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
|
CA3160162A1
(en)
|
2019-11-04 |
2021-05-14 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
MX2022005400A
(es)
|
2019-11-06 |
2022-05-24 |
Genentech Inc |
Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
|
KR20220101147A
(ko)
|
2019-11-14 |
2022-07-19 |
웨어울프 세라퓨틱스, 인크. |
활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법
|
CA3156713A1
(en)
|
2019-11-20 |
2021-05-27 |
Daisuke Kameoka |
Antibody-containing preparation
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
AU2020395319A1
(en)
|
2019-12-06 |
2022-07-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to BCMA-targeted binding domains and related compositions and methods
|
CN115335399A
(zh)
|
2019-12-06 |
2022-11-11 |
朱诺治疗学股份有限公司 |
针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
CR20220330A
(es)
|
2019-12-13 |
2022-08-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y métodos de uso.
|
AU2020406738A1
(en)
|
2019-12-20 |
2022-06-23 |
Intervet International B.V. |
Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
|
CA3162031A1
(en)
|
2019-12-20 |
2021-06-24 |
Mohamad Morsey |
Canine interleukin-4 receptor alpha antibodies
|
CN115279388A
(zh)
|
2019-12-20 |
2022-11-01 |
百时美施贵宝公司 |
岩藻糖基化抑制剂用于生产无岩藻糖基化抗体的用途
|
CN110964090B
(zh)
*
|
2019-12-26 |
2021-02-19 |
江南大学 |
一种促进n-乙酰氨基葡萄糖生产的蛋白质起始因子if3突变体及其应用
|
AR120898A1
(es)
|
2019-12-26 |
2022-03-30 |
Univ Osaka |
Agente para tratar o prevenir neuromielitis óptica en fase aguda
|
IL294226B2
(en)
|
2019-12-27 |
2025-05-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CTLA-4 antibodies and their use
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
TWI877278B
(zh)
|
2019-12-30 |
2025-03-21 |
美商思進公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
BR112022013944A2
(pt)
|
2020-01-15 |
2022-09-20 |
Univ Osaka |
Agente profilático ou terapêutico para demência
|
AU2021208532A1
(en)
|
2020-01-16 |
2022-07-07 |
Genmab A/S |
Formulations of CD38 antibodies and uses thereof
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
MX2022009391A
(es)
|
2020-01-31 |
2022-09-26 |
Genentech Inc |
Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
|
AU2021214795A1
(en)
|
2020-01-31 |
2022-08-18 |
The Cleveland Clinic Foundation |
Anti-Müllerian Hormone Receptor 2 antibodies and methods of use
|
EP4100435A1
(en)
|
2020-02-05 |
2022-12-14 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
MX2022009819A
(es)
|
2020-02-12 |
2022-09-05 |
Chugai Pharmaceutical Co Ltd |
Moleculas de union al antigeno anti-grupo de diferenciacion 137 (cd137) para usarse en el tratamiento contra el cancer.
|
JPWO2021162098A1
(forum.php)
|
2020-02-14 |
2021-08-19 |
|
|
US11692038B2
(en)
|
2020-02-14 |
2023-07-04 |
Gilead Sciences, Inc. |
Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
|
EP4093762A1
(en)
|
2020-02-20 |
2022-11-30 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
WO2021170020A1
(en)
|
2020-02-27 |
2021-09-02 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Antibodies binding il4r and uses thereof
|
WO2021170071A1
(en)
|
2020-02-28 |
2021-09-02 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137 constructs, multispecific antibody and uses thereof
|
CA3169939A1
(en)
|
2020-02-28 |
2021-09-02 |
Jie Xue |
Anti-cd137 construct and use thereof
|
BR112022018088A2
(pt)
|
2020-03-12 |
2023-01-17 |
Immune Onc Therapeutics Inc |
Novos anticorpos anti-lilrb4 e produtos derivados
|
CA3175279A1
(en)
|
2020-03-12 |
2021-09-16 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
WO2021182570A1
(ja)
|
2020-03-12 |
2021-09-16 |
東レ株式会社 |
癌の治療及び/又は予防のための医薬品
|
KR20220152309A
(ko)
|
2020-03-12 |
2022-11-15 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
WO2021182573A1
(ja)
|
2020-03-12 |
2021-09-16 |
東レ株式会社 |
癌の治療及び/又は予防のための医薬品
|
WO2021182572A1
(ja)
|
2020-03-12 |
2021-09-16 |
東レ株式会社 |
癌の治療及び/又は予防のための医薬品
|
EP4118114A1
(en)
|
2020-03-13 |
2023-01-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
PE20230259A1
(es)
|
2020-03-19 |
2023-02-07 |
Genentech Inc |
Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
|
TW202202521A
(zh)
|
2020-03-23 |
2022-01-16 |
美商必治妥美雅史谷比公司 |
用於治療癌症之抗ccr8抗體
|
EP4126949A1
(en)
|
2020-03-24 |
2023-02-08 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
SMT202400070T1
(it)
|
2020-03-26 |
2024-03-13 |
Univ Vanderbilt |
Anticorpi monoclonali umani contro coronavirus 2 da sindrome respiratoria acuta grave (sars-cov-2)
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
CN120058957A
(zh)
|
2020-03-30 |
2025-05-30 |
国立大学法人三重大学 |
双特异性抗体
|
US20230159662A1
(en)
|
2020-04-01 |
2023-05-25 |
Kyowa Kirin Co., Ltd. |
Antibody composition
|
WO2021202235A1
(en)
|
2020-04-01 |
2021-10-07 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
BR112022021441A2
(pt)
|
2020-04-24 |
2022-12-13 |
Genentech Inc |
Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
|
EP4143225A4
(en)
|
2020-04-27 |
2024-05-15 |
The Regents of the University of California |
ISOFORM-INDEPENDENT ANTIBODIES AGAINST LIPOPROTEIN(A)
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
WO2021219871A2
(en)
|
2020-04-30 |
2021-11-04 |
Aduro Biotech Holdings, Europe B.V. |
Anti-cd103 antibodies
|
KR20230087414A
(ko)
|
2020-05-03 |
2023-06-16 |
레베나 (쑤저우) 바이오파마 컴퍼니 리미티드 |
항-Trop-2 항체를 포함하는 항체-약물 접합체 (ADCS), 상기 ADCS를 포함하는 조성물, 및 이의 제조 및 사용 방법
|
WO2021228956A1
(en)
|
2020-05-12 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
EP4151654A4
(en)
|
2020-05-12 |
2024-11-27 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
St2 antigen binding protein
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
KR20230010749A
(ko)
|
2020-05-17 |
2023-01-19 |
아스트라제네카 유케이 리미티드 |
Sars-cov-2 항체 및 이를 선택 및 이용하는 방법
|
WO2021242815A1
(en)
|
2020-05-26 |
2021-12-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
EP4157881A4
(en)
|
2020-05-27 |
2024-10-09 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
ANTIBODIES THAT SPECIFICALLY RECOGNIZE NERVE GROWTH FACTOR AND THEIR USES
|
BR112022024339A2
(pt)
|
2020-05-29 |
2022-12-27 |
23Andme Inc |
Anticorpos anti cd200r1 e métodos de uso dos mesmos
|
CA3185858A1
(en)
|
2020-06-02 |
2021-12-09 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
JP2023528441A
(ja)
|
2020-06-03 |
2023-07-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗SARS-CoV-2スパイク糖タンパク質抗体を用いてSARS-CoV-2感染及びCOVID-19を治療又は予防するための方法
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
JP2023529206A
(ja)
|
2020-06-12 |
2023-07-07 |
ジェネンテック, インコーポレイテッド |
がん免疫療法のための方法及び組成物
|
JP2023531406A
(ja)
|
2020-06-16 |
2023-07-24 |
ジェネンテック, インコーポレイテッド |
トリプルネガティブ乳がんを処置するための方法および組成物
|
JP2023531200A
(ja)
|
2020-06-18 |
2023-07-21 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体及びpd-1軸結合アンタゴニストを用いた治療
|
CN116234824A
(zh)
|
2020-06-22 |
2023-06-06 |
阿尔米雷尔有限公司 |
抗il-36抗体及其使用方法
|
US20240228648A1
(en)
|
2020-06-23 |
2024-07-11 |
Jiangsu Kanion Pharmaceutical Co., Ltd. |
Anti-cd38 antibody and use thereof
|
US20230265175A1
(en)
|
2020-06-25 |
2023-08-24 |
Merck Sharp & Dohme Llc |
High affinity antibodies targeting tau phosphorylated at serine 413
|
CN115803053A
(zh)
|
2020-06-30 |
2023-03-14 |
江苏恒瑞医药股份有限公司 |
抗cd70抗体及其应用
|
KR20230041023A
(ko)
|
2020-07-17 |
2023-03-23 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 제조 방법
|
EP4183420A4
(en)
|
2020-07-20 |
2025-03-05 |
Daiichi Sankyo Company, Limited |
COMBINATION OF (ANTI-HER2 ANTIBODY) DRUG CONJUGATE AND HER DIMERIZATION INHIBITOR
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
CA3190328A1
(en)
|
2020-07-29 |
2022-02-03 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
WO2022029660A1
(en)
|
2020-08-05 |
2022-02-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
CN116234830A
(zh)
|
2020-08-07 |
2023-06-06 |
基因泰克公司 |
Flt3配体融合蛋白及使用方法
|
TW202221025A
(zh)
|
2020-08-10 |
2022-06-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19的sars—cov—2抗體
|
WO2022036079A1
(en)
|
2020-08-13 |
2022-02-17 |
Bristol-Myers Squibb Company |
Methods of redirecting of il-2 to target cells of interest
|
AR123254A1
(es)
|
2020-08-14 |
2022-11-16 |
Ac Immune Sa |
Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
WO2022043517A2
(en)
|
2020-08-27 |
2022-03-03 |
Cureab Gmbh |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
KR102269716B1
(ko)
|
2020-09-01 |
2021-06-28 |
추가이 세이야쿠 가부시키가이샤 |
Il-31 안타고니스트를 유효 성분으로서 함유하는, 투석 소양증의 예방용 및/또는 치료용 의약 조성물
|
TW202227496A
(zh)
|
2020-09-14 |
2022-07-16 |
瑞士商伊克諾斯科學公司 |
結合至il1rap之抗體及其用途
|
EP4222172A1
(en)
|
2020-09-30 |
2023-08-09 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
IL301764A
(en)
|
2020-09-30 |
2023-05-01 |
Dren Bio Inc |
Anti-cd94 antibodies and methods of use thereof
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
CA3195019A1
(en)
|
2020-10-06 |
2022-04-14 |
Maria Fardis |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4225373A4
(en)
|
2020-10-07 |
2025-01-08 |
Dren Bio, Inc. |
ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
|
US11926667B2
(en)
|
2020-10-13 |
2024-03-12 |
Janssen Biotech, Inc. |
Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
|
AU2021360782A1
(en)
|
2020-10-14 |
2023-06-08 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
EP4232475A1
(en)
|
2020-10-20 |
2023-08-30 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
|
AU2021363536A1
(en)
|
2020-10-20 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors
|
US20230400467A1
(en)
|
2020-10-26 |
2023-12-14 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
TW202227481A
(zh)
|
2020-11-04 |
2022-07-16 |
美國洛克菲勒大學 |
中和抗sars-cov-2抗體
|
MX2023005130A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
|
US12351643B2
(en)
|
2020-11-04 |
2025-07-08 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
AU2021374594A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
EP4240769A1
(en)
|
2020-11-06 |
2023-09-13 |
Bristol-Myers Squibb Company |
Dosing and administration of non-fucosylated anti-ctla-4 antibody as monotherapy
|
JP2023547506A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
B細胞悪性腫瘍を治療するための抗cd19剤及びb細胞標的化剤の組み合わせ療法
|
MX2023005353A
(es)
|
2020-11-06 |
2023-05-22 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas.
|
IL302812A
(en)
|
2020-11-11 |
2023-07-01 |
Daiichi Sankyo Co Ltd |
Combinations of an antibody-drug conjugate with anti-sirp alpha antibody
|
WO2022102695A1
(ja)
|
2020-11-12 |
2022-05-19 |
第一三共株式会社 |
抗b7-h3抗体-薬物コンジュゲート投与による中皮腫の治療
|
CA3199006A1
(en)
|
2020-11-20 |
2022-05-27 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-cd25 antibodies
|
EP4247496A1
(en)
|
2020-11-20 |
2023-09-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Anti-cd25 antibodies
|
KR20230113581A
(ko)
|
2020-11-25 |
2023-07-31 |
실리오 디벨럽먼트, 인크. |
종양 특이적 절단성 링커
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
WO2022125941A1
(en)
|
2020-12-11 |
2022-06-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
EP4262827A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
AU2021401302A1
(en)
|
2020-12-17 |
2023-07-06 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
WO2022136569A1
(en)
|
2020-12-23 |
2022-06-30 |
Cantargia Ab |
Anti-il1rap antibody
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
CN114685669A
(zh)
|
2020-12-30 |
2022-07-01 |
和铂医药(苏州)有限公司 |
结合trop2的抗体及其用途
|
CA3203382A1
(en)
|
2020-12-31 |
2022-07-07 |
Adrian Emanual Wells |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
JP2024503394A
(ja)
|
2021-01-08 |
2024-01-25 |
北京韓美薬品有限公司 |
4-1bbと特異的に結合する抗体及びその抗原結合フラグメント
|
JP7699210B2
(ja)
|
2021-01-08 |
2025-06-26 |
北京韓美薬品有限公司 |
Cd47と特異的に結合する抗体及びその抗原結合フラグメント
|
TW202245844A
(zh)
|
2021-01-13 |
2022-12-01 |
紀念斯隆凱特琳癌症中心 |
抗dll3抗體-藥物結合物
|
EP4277664A1
(en)
|
2021-01-13 |
2023-11-22 |
Memorial Sloan Kettering Cancer Center |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
WO2022155324A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
US20240076373A1
(en)
|
2021-01-28 |
2024-03-07 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
KR20230147099A
(ko)
|
2021-01-28 |
2023-10-20 |
백신벤트 게엠베하 |
B 세포 매개 면역 반응을 조절하기 위한 방법 및 수단(method and means for modulating b-cell mediated immune responses)
|
WO2022165266A1
(en)
|
2021-01-28 |
2022-08-04 |
Compugen Ltd. |
Anti-pvrig antibodies formulations and uses thereof
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
JP2024506557A
(ja)
|
2021-01-29 |
2024-02-14 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用
|
US20240117011A1
(en)
|
2021-02-09 |
2024-04-11 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
AU2022220611A1
(en)
|
2021-02-09 |
2023-08-24 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
MX2023009497A
(es)
|
2021-02-15 |
2023-08-23 |
Takeda Pharmaceuticals Co |
Composiciones y metodos de terapia celular para modular la se?alizacion del factor de crecimiento transformador-beta (tgf-beta).
|
AR124914A1
(es)
|
2021-02-18 |
2023-05-17 |
Mitsubishi Tanabe Pharma Corp |
Nuevo anticuerpo anti-pad4
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
EP4301781A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
WO2022184082A1
(en)
|
2021-03-03 |
2022-09-09 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
AR126323A1
(es)
|
2021-03-05 |
2023-10-04 |
Iovance Biotherapeutics Inc |
Composiciones para el almacenamiento de tumores y cultivos celulares
|
US20240141048A1
(en)
|
2021-03-05 |
2024-05-02 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
CA3211581A1
(en)
|
2021-03-10 |
2022-09-15 |
Ellen WU |
Immunomodulatory molecules and uses thereof
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
TW202300521A
(zh)
|
2021-03-15 |
2023-01-01 |
美商建南德克公司 |
治療狼瘡性腎炎的組成物及方法
|
NZ804536A
(en)
|
2021-03-18 |
2024-12-20 |
Medimmune Ltd |
Therapeutic binding molecule that binds to ccr9
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
TW202304480A
(zh)
|
2021-03-19 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球(til)中之與cd39/cd69選擇及基因剔除相關之til擴增之方法
|
KR20240012352A
(ko)
|
2021-03-23 |
2024-01-29 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
T 세포 림프종의 진단 및 치료 방법
|
WO2022204155A1
(en)
|
2021-03-23 |
2022-09-29 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
US20220313806A1
(en)
|
2021-03-25 |
2022-10-06 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
JP2024511424A
(ja)
|
2021-03-25 |
2024-03-13 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗igfbp7構築物およびその使用
|
AU2022246048A1
(en)
|
2021-03-26 |
2023-08-31 |
Innate Pharma |
Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
|
WO2022210485A1
(ja)
|
2021-03-29 |
2022-10-06 |
第一三共株式会社 |
安定な多重特異性分子及びその利用
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
AU2022263418A1
(en)
|
2021-04-19 |
2023-10-26 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
JP2024514281A
(ja)
|
2021-04-23 |
2024-04-01 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Nk細胞係合剤関連の有害作用の防止または軽減
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
IL308351A
(en)
|
2021-05-12 |
2024-01-01 |
Genentech Inc |
Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
|
WO2022241235A1
(en)
|
2021-05-14 |
2022-11-17 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
AU2022273303A1
(en)
|
2021-05-14 |
2023-11-02 |
Genentech, Inc. |
Agonists of trem2
|
US20230115257A1
(en)
|
2021-05-17 |
2023-04-13 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
US20220372114A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
EP4340850A1
(en)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
CN117396513A
(zh)
|
2021-05-28 |
2024-01-12 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的联合疗法
|
EP4155321A1
(en)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
AU2022289365A1
(en)
|
2021-06-07 |
2023-12-14 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
WO2022258600A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
WO2022258662A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
BR112023025476A2
(pt)
|
2021-06-09 |
2024-02-27 |
Innate Pharma |
Proteína de ligação multimérica e seu método de produção, composição farmacêutica, molécula de ácido nucleico isolada, vetor de expressão, célula isolada e proteína de ligação para uso
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
CA3222880A1
(en)
|
2021-06-18 |
2022-12-22 |
Jeffrey Stavenhagen |
Antibodies which bind human fibrin or fibrinogen ?c domain and methods of use
|
US20240294626A1
(en)
|
2021-06-22 |
2024-09-05 |
Novartis Ag |
Bispecific antibodies for use in treatment of hidradenitis suppurativa
|
CN117545508A
(zh)
|
2021-06-23 |
2024-02-09 |
东丽株式会社 |
用于癌的治疗和/或预防的药品
|
US20250228937A1
(en)
|
2021-06-23 |
2025-07-17 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
TWI864408B
(zh)
|
2021-06-25 |
2024-12-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
WO2022270611A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ctla-4抗体
|
CA3221281A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
EP4363450A1
(en)
|
2021-07-01 |
2024-05-08 |
Compugen Ltd. |
Anti-tigit and anti-pvrig in monotherapy and combination treatments
|
WO2023283611A1
(en)
|
2021-07-08 |
2023-01-12 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
MX2024000563A
(es)
|
2021-07-14 |
2024-04-10 |
Regeneron Pharma |
Anticuerpos y fragmentos de union al antigeno anti-glicoproteína de la espícula de sars-cov-2.
|
CN115812082A
(zh)
|
2021-07-14 |
2023-03-17 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
AU2022309554A1
(en)
|
2021-07-14 |
2024-02-22 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
|
EP4373270A2
(en)
|
2021-07-22 |
2024-05-29 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
KR20240042416A
(ko)
|
2021-07-27 |
2024-04-02 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
JPWO2023008462A1
(forum.php)
|
2021-07-27 |
2023-02-02 |
|
|
AU2022316644A1
(en)
|
2021-07-27 |
2024-02-29 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
EP4377446A1
(en)
|
2021-07-28 |
2024-06-05 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
US20240369568A1
(en)
|
2021-08-03 |
2024-11-07 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical Compositions and Stable Isotope Labeling Peptide Mapping Method
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
CN117897409A
(zh)
|
2021-08-13 |
2024-04-16 |
基因泰克公司 |
抗类胰蛋白酶抗体的给药
|
MX2024001925A
(es)
|
2021-08-13 |
2024-07-09 |
Glaxosmithkline Ip Dev Ltd |
Quimeras dirigidas a la citotoxicidad para células que expresan ccr2.
|
WO2023017484A1
(en)
|
2021-08-13 |
2023-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras
|
JP2024534067A
(ja)
|
2021-08-19 |
2024-09-18 |
エフ. ホフマン-ラ ロシュ アーゲー |
多価抗バリアントfc領域抗体および使用方法
|
CN117836326A
(zh)
|
2021-08-26 |
2024-04-05 |
协和麒麟株式会社 |
与cd116和cd131结合的双特异性抗体
|
WO2023028591A1
(en)
|
2021-08-27 |
2023-03-02 |
Genentech, Inc. |
Methods of treating tau pathologies
|
TW202325727A
(zh)
|
2021-08-30 |
2023-07-01 |
美商建南德克公司 |
抗聚泛素多特異性抗體
|
US20250281630A1
(en)
|
2021-09-03 |
2025-09-11 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
AU2022338208A1
(en)
|
2021-09-06 |
2024-03-21 |
Genmab A/S |
Antibodies capable of binding to cd27, variants thereof and uses thereof
|
KR20240109615A
(ko)
|
2021-09-09 |
2024-07-11 |
이오반스 바이오테라퓨틱스, 인크. |
Pd-1 talen 녹다운을 사용한 til 생성물의 생성 방법
|
CA3231632A1
(en)
|
2021-09-15 |
2023-03-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
CN118369344A
(zh)
|
2021-09-16 |
2024-07-19 |
阿博莱斯制药公司 |
抗人cd45rc结合结构域及其用途
|
AU2022345251A1
(en)
|
2021-09-17 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
EP4404969A1
(en)
|
2021-09-24 |
2024-07-31 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
CN115894689A
(zh)
|
2021-09-30 |
2023-04-04 |
百奥泰生物制药股份有限公司 |
抗b7-h3抗体及其应用
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
WO2023057567A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
US20240409638A1
(en)
|
2021-10-07 |
2024-12-12 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
AR127269A1
(es)
|
2021-10-08 |
2024-01-03 |
Chugai Pharmaceutical Co Ltd |
Formulación de anticuerpo anti-hla-dq2.5
|
WO2023064958A1
(en)
|
2021-10-15 |
2023-04-20 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
EP4420683A1
(en)
|
2021-10-18 |
2024-08-28 |
Daiichi Sankyo Company, Limited |
Anti-cd37 antibody-drug conjugate
|
WO2023077015A2
(en)
|
2021-10-27 |
2023-05-04 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
KR20240099315A
(ko)
|
2021-11-05 |
2024-06-28 |
아메리칸 다이어그노스틱스 앤드 테라피, 엘엘씨 (에이디엑스알엑스) |
암배아성 항원에 대한 단클론성 항체 및 이의 용도
|
WO2023081434A2
(en)
|
2021-11-07 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
US20250032618A1
(en)
|
2021-11-10 |
2025-01-30 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
EP4430072A1
(en)
|
2021-11-10 |
2024-09-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
AR127692A1
(es)
|
2021-11-16 |
2024-02-21 |
Ac Immune Sa |
Anticuerpos anti-asc para uso en tratamientos antiinflamatorios
|
MX2024005680A
(es)
|
2021-11-16 |
2024-05-30 |
Genentech Inc |
Metodos y composiciones para tratar lupus eritematoso sistemico (sle) con mosunetuzumab.
|
WO2023089527A1
(en)
|
2021-11-18 |
2023-05-25 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
EP4438055A1
(en)
|
2021-11-25 |
2024-10-02 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Anti-siglec-15 antibody and use thereof
|
EP4186529B1
(en)
|
2021-11-25 |
2025-07-09 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
AU2022395626A1
(en)
|
2021-11-25 |
2024-05-30 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
IL312728A
(en)
|
2021-11-30 |
2024-07-01 |
Daiichi Sankyo Co Ltd |
Protease-cleavable masked antibodies
|
CN116829179A
(zh)
|
2021-12-06 |
2023-09-29 |
北京三诺佳邑生物技术有限责任公司 |
特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
EP4448579A1
(en)
|
2021-12-17 |
2024-10-23 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
CN118488965A
(zh)
|
2021-12-17 |
2024-08-13 |
上海复宏汉霖生物技术股份有限公司 |
抗ox40抗体、多特异性抗体及其使用方法
|
EP4456922A1
(en)
|
2021-12-28 |
2024-11-06 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and atr inhibitor
|
US20250161305A1
(en)
|
2021-12-28 |
2025-05-22 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and rasg12c inhibitor
|
PE20242347A1
(es)
|
2022-01-07 |
2024-12-16 |
Johnson And Johnson Entpr Innovation Inc |
Materiales y metodos de proteinas de union a il-1 beta
|
US20250101089A1
(en)
|
2022-01-24 |
2025-03-27 |
Cambridge Enterprise Limited |
Tau therapy
|
EP4469159A1
(en)
|
2022-01-27 |
2024-12-04 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
JP2025504908A
(ja)
|
2022-01-28 |
2025-02-19 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
サイトカイン関連腫瘍浸潤リンパ球組成物及び方法
|
US20250067745A1
(en)
|
2022-01-31 |
2025-02-27 |
Institut National de la Santé et de la Recherche Médicale |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
JPWO2023153442A1
(forum.php)
|
2022-02-09 |
2023-08-17 |
|
|
KR20240141760A
(ko)
|
2022-02-09 |
2024-09-27 |
고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼 |
Fcrl1에 결합하는 항체 또는 해당 항체 단편
|
IL314799A
(en)
|
2022-02-10 |
2024-10-01 |
Us Health |
Human monoclonal antibodies that broadly target coronaviruses
|
EP4477665A4
(en)
|
2022-02-10 |
2025-08-20 |
Affyxell Therapeutics Co Ltd |
STEFIN A PROTEIN VARIANTS THAT SPECIFICALLY BIND TO CD40L AND THEIR USES
|
IL315043A
(en)
|
2022-02-16 |
2024-10-01 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Rq生物科技有限公司 |
抗體
|
MA67298A1
(fr)
|
2022-02-18 |
2025-03-28 |
Rakuten Medical, Inc. |
Molécules d'anticorps anti-ligand de mort cellulaire programmée 1 (pd-l1), polynucléotides de codage et méthodes d'utilisation
|
WO2023161875A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
|
WO2023161878A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for folate receptor-expressing cells
|
WO2023161879A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
|
WO2023161881A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
WO2023161876A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for cxcr3-expressing cells
|
WO2023161877A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for integrin avb6-expressing cells
|
JP2025508845A
(ja)
|
2022-02-25 |
2025-04-10 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
C-cケモカイン受容体2発現細胞のための細胞傷害性標的キメラ
|
JP2025509286A
(ja)
|
2022-03-10 |
2025-04-11 |
ビバソル, インコーポレイテッド |
抗体-薬物コンジュゲートおよびその使用
|
JP2025509832A
(ja)
|
2022-03-15 |
2025-04-11 |
コンピュジェン リミテッド |
Il-18bpアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用
|
KR20240165390A
(ko)
|
2022-03-16 |
2024-11-22 |
아스트라제네카 유케이 리미티드 |
항-trop2 항체-약물 접합체 요법에 대한 점수산정 방법
|
TW202400232A
(zh)
|
2022-03-16 |
2024-01-01 |
日商第一三共股份有限公司 |
多特異性分子與免疫檢查點抑制劑之組合
|
US20240103010A1
(en)
|
2022-03-18 |
2024-03-28 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
MX2024011468A
(es)
|
2022-03-23 |
2024-09-25 |
Hoffmann La Roche |
Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
|
CN118974096A
(zh)
|
2022-03-25 |
2024-11-15 |
上海复宏汉霖生物技术股份有限公司 |
抗msln抗体及使用方法
|
WO2023192827A1
(en)
|
2022-03-26 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to hiv-1 env and their use
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
JP2025510997A
(ja)
|
2022-03-30 |
2025-04-15 |
ノバルティス アーゲー |
抗ナトリウム利尿ペプチド受容体1(npr1)抗体を使用して障害を治療する方法
|
IL315770A
(en)
|
2022-04-01 |
2024-11-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
JP2025512313A
(ja)
|
2022-04-06 |
2025-04-17 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
AU2023250038A1
(en)
|
2022-04-08 |
2024-11-14 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
EP4508432A1
(en)
|
2022-04-11 |
2025-02-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
JP2025512342A
(ja)
|
2022-04-13 |
2025-04-17 |
ジェネンテック, インコーポレイテッド |
治療用タンパク質の医薬組成物および使用方法
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
AU2023258146A1
(en)
|
2022-04-20 |
2024-09-05 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
TW202400140A
(zh)
|
2022-04-27 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合
|
CN119836433A
(zh)
|
2022-04-29 |
2025-04-15 |
阿斯利康(英国)有限公司 |
Sars-cov-2抗体及其使用方法
|
AR129182A1
(es)
|
2022-04-29 |
2024-07-24 |
23Andme Inc |
Proteínas de unión al antígeno
|
EP4519322A1
(en)
|
2022-05-03 |
2025-03-12 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023217068A1
(zh)
|
2022-05-09 |
2023-11-16 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别gdf15的抗体及其应用
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
CN119403829A
(zh)
|
2022-05-11 |
2025-02-07 |
第一三共株式会社 |
对于肿瘤抗原特异性的抗体和cd47抑制剂的组合
|
IL316738A
(en)
|
2022-05-11 |
2024-12-01 |
Genentech Inc |
Dosage for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
WO2023222886A1
(en)
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
JP2025517908A
(ja)
|
2022-05-24 |
2025-06-12 |
第一三共株式会社 |
抗cdh6抗体-薬物コンジュゲートの投薬量レジメン
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
JPWO2023234427A1
(forum.php)
|
2022-06-03 |
2023-12-07 |
|
|
WO2023234426A1
(ja)
|
2022-06-03 |
2023-12-07 |
Ube株式会社 |
抗体・複数薬物コンジュゲート
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
EP4536701A2
(en)
|
2022-06-08 |
2025-04-16 |
Institute for Research in Biomedicine (IRB) |
Cross-specific antibodies, uses and methods for discovery thereof
|
AU2023286645A1
(en)
|
2022-06-23 |
2025-01-16 |
Fortvita Biologics (Singapore) Pte.Ltd. |
Bispecific antibody binding egfr and b7-h3
|
EP4548932A1
(en)
|
2022-06-30 |
2025-05-07 |
Toray Industries, Inc. |
Pharmaceutical composition for treating and/or preventing cancer
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
KR20250039386A
(ko)
|
2022-07-13 |
2025-03-20 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법
|
TW202417503A
(zh)
|
2022-07-19 |
2024-05-01 |
美商舒泰神(加州)生物科技有限公司 |
特異性識別b和t淋巴細胞衰減器(btla)的抗體及其應用
|
EP4558524A1
(en)
|
2022-07-19 |
2025-05-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
IL318084A
(en)
|
2022-07-22 |
2025-02-01 |
Bristol Myers Squibb Co |
Antibodies that bind to HUMAN PAD4 and its uses
|
PE20250796A1
(es)
|
2022-07-22 |
2025-03-14 |
Genentech Inc |
Moleculas de union al antigeno anti-steap1 y sus usos
|
EP4558823A1
(en)
|
2022-07-22 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
EP4561635A1
(en)
|
2022-07-28 |
2025-06-04 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
WO2024026496A1
(en)
|
2022-07-28 |
2024-02-01 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
EP4565683A1
(en)
|
2022-08-01 |
2025-06-11 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
CN120077064A
(zh)
|
2022-08-05 |
2025-05-30 |
詹森生物科技公司 |
用于治疗脑肿瘤的转铁蛋白受体结合蛋白
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
WO2024031032A1
(en)
|
2022-08-05 |
2024-02-08 |
Bristol-Myers Squibb Company |
Anti-ctla-4 antibodies for treatment of kras mutant cancers
|
WO2024037633A2
(en)
|
2022-08-19 |
2024-02-22 |
Evive Biotechnology (Shanghai) Ltd |
Formulations comprising g-csf and uses thereof
|
EP4577578A1
(en)
|
2022-08-22 |
2025-07-02 |
Abdera Therapeutics Inc. |
Dll3 binding molecules and uses thereof
|
AU2023329563A1
(en)
|
2022-08-24 |
2025-02-27 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
EP4578459A1
(en)
|
2022-08-24 |
2025-07-02 |
Toray Industries, Inc. |
Pharmaceutical product for treatment and/or prevention of cancer
|
EP4578457A1
(en)
|
2022-08-24 |
2025-07-02 |
Toray Industries, Inc. |
Pharmaceutical for treating and/or preventing cancer
|
WO2024044675A1
(en)
|
2022-08-25 |
2024-02-29 |
Beigene, Ltd. |
Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
|
CN119790068A
(zh)
|
2022-08-25 |
2025-04-08 |
葛兰素史克知识产权发展有限公司 |
抗原结合蛋白及其用途
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
AU2023334695A1
(en)
|
2022-08-30 |
2025-02-27 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
CN119768184A
(zh)
|
2022-08-30 |
2025-04-04 |
东丽株式会社 |
用于癌的治疗和/或预防的药品
|
EP4581366A1
(en)
|
2022-09-01 |
2025-07-09 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
CN120077071A
(zh)
|
2022-09-07 |
2025-05-30 |
当康生物技术有限责任公司 |
抗vista构建体及其用途
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
IL319568A
(en)
|
2022-09-15 |
2025-05-01 |
Avidicure Ip B V |
Multispecific antigen-binding proteins for NK cell stimulation and their uses
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
EP4596580A1
(en)
|
2022-09-27 |
2025-08-06 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibody for specifically recognizing light and use thereof
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
AU2023365967A1
(en)
|
2022-10-20 |
2025-06-05 |
Beijing Solobio Genetechnology Co., Ltd. |
Antibody combination specifically binding to trail or fasl, and bispecific antibody
|
IL320355A
(en)
|
2022-10-25 |
2025-06-01 |
Genentech Inc |
Therapeutic and diagnostic methods for multiple myeloma
|
CN120051301A
(zh)
|
2022-11-04 |
2025-05-27 |
吉利德科学公司 |
使用抗ccr8抗体、化学疗法和免疫疗法组合的抗癌疗法
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
EP4612277A1
(en)
|
2022-11-04 |
2025-09-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
AR130982A1
(es)
|
2022-11-07 |
2025-02-05 |
Univ Osaka |
Agente preventivo o terapéutico para enfermedades asociadas con la agregación de proteínas anormales
|
EP4615872A1
(en)
|
2022-11-08 |
2025-09-17 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
EP4615580A1
(en)
|
2022-11-09 |
2025-09-17 |
CIS Biopharma AG |
Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
|
WO2024107752A2
(en)
|
2022-11-15 |
2024-05-23 |
Onestone Therapeutics Llc |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|
KR20250106304A
(ko)
|
2022-11-17 |
2025-07-09 |
사노피 |
Ceacam5 항체-약물 접합체 및 이의 사용 방법
|
CN120584182A
(zh)
|
2022-11-21 |
2025-09-02 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞扩增的二维过程及其疗法
|
WO2024112711A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Methods for assessing proliferation potency of gene-edited t cells
|
TW202434306A
(zh)
|
2022-11-24 |
2024-09-01 |
瑞士商百濟神州瑞士有限責任公司 |
抗cea抗體藥物軛合物及使用方法
|
TW202436348A
(zh)
|
2022-11-25 |
2024-09-16 |
日商中外製藥股份有限公司 |
蛋白質的製造方法
|
TW202440169A
(zh)
|
2022-11-30 |
2024-10-16 |
日商第一三共股份有限公司 |
抗體-藥物結合物與dnmt抑制劑之組合
|
AU2023393437A1
(en)
|
2022-12-16 |
2025-06-19 |
Pheon Therapeutics Ltd |
Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
|
WO2024137381A1
(en)
|
2022-12-19 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies for treating sars-cov-2 infection
|
AU2023411604A1
(en)
|
2022-12-23 |
2025-06-26 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
CN120603850A
(zh)
|
2023-01-19 |
2025-09-05 |
广州百济神州生物制药有限公司 |
抗cmet抗体及使用方法
|
TW202434310A
(zh)
|
2023-01-27 |
2024-09-01 |
日商第一三共股份有限公司 |
抗lrrc15抗體
|
WO2024170543A1
(en)
|
2023-02-14 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cd44 antibodies and uses thereof
|
WO2024182443A2
(en)
|
2023-02-27 |
2024-09-06 |
Compugen Ltd. |
Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
|
WO2024183636A1
(en)
|
2023-03-03 |
2024-09-12 |
Beigene Switzerland Gmbh |
Cd16a antibodies and methods of use
|
WO2024183637A1
(en)
|
2023-03-03 |
2024-09-12 |
Beigene Switzerland Gmbh |
Muc1 antibodies and methods of use
|
WO2024183635A1
(en)
|
2023-03-03 |
2024-09-12 |
Beigene, Ltd. |
Muc1 and cd16a antibodies and methods of use
|
WO2024186635A2
(en)
|
2023-03-03 |
2024-09-12 |
Celldex Therapeutics, Inc. |
Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
|
AR132064A1
(es)
|
2023-03-06 |
2025-05-21 |
Beigene Switzerland Gmbh |
Anticuerpos anti-cldn6 y métodos de uso
|
TW202436345A
(zh)
|
2023-03-06 |
2024-09-16 |
瑞士商百濟神州瑞士有限責任公司 |
抗cd3多特異性抗體及使用方法
|
WO2024184810A1
(en)
|
2023-03-06 |
2024-09-12 |
Beigene Switzerland Gmbh |
Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
|
WO2024184494A1
(en)
|
2023-03-08 |
2024-09-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules and uses thereof
|
FR3147278A1
(fr)
|
2023-03-31 |
2024-10-04 |
Avacta Life Sciences Limited |
Polypeptides de liaison au tnfr2 et procedes d'utilisation
|
WO2024200987A1
(en)
|
2023-03-31 |
2024-10-03 |
Avacta Life Sciences Limited |
Tnfr2 binding polypeptides and methods of use
|
WO2024206738A1
(en)
|
2023-03-31 |
2024-10-03 |
Immunai Inc. |
Humanized anti-trem2 antibodies
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2024211236A2
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2024212827A1
(en)
|
2023-04-12 |
2024-10-17 |
Shanghai Kangabio Co., Limited |
Multifunctional molecules comprising masked interleukin 12 and methods of use
|
WO2024220546A2
(en)
|
2023-04-17 |
2024-10-24 |
Peak Bio, Inc. |
Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
|
WO2024218345A1
(en)
|
2023-04-21 |
2024-10-24 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
|
WO2024218361A1
(en)
|
2023-04-21 |
2024-10-24 |
Glaxosmithkline Intellectual Property Development Limited |
Bispecific cytotoxicity targeting chimeras
|
TW202506193A
(zh)
|
2023-04-24 |
2025-02-16 |
美商默沙東有限責任公司 |
Trop2結合劑及其結合物
|
TW202448949A
(zh)
|
2023-05-05 |
2024-12-16 |
美商建南德克公司 |
用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
|
WO2024231251A1
(en)
|
2023-05-05 |
2024-11-14 |
Cantargia Ab |
Anti-il1rap antibodies
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
US12410258B2
(en)
|
2023-05-12 |
2025-09-09 |
Ganmab A/S |
Antibodies capable of binding to OX40, variants thereof and uses thereof
|
WO2024243355A1
(en)
|
2023-05-24 |
2024-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
|
WO2024254455A1
(en)
|
2023-06-08 |
2024-12-12 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|
EP4477236A1
(en)
|
2023-06-14 |
2024-12-18 |
Inatherys |
Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
|
WO2024263845A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Treatment of multiple myeloma
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
WO2025002410A1
(en)
|
2023-06-30 |
2025-01-02 |
Evive Biotechnology (Shanghai) Ltd |
G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
WO2025015318A2
(en)
|
2023-07-13 |
2025-01-16 |
Iovance Biotherapeutics, Inc. |
Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
|
WO2025019790A1
(en)
|
2023-07-19 |
2025-01-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
|
WO2025024233A1
(en)
|
2023-07-21 |
2025-01-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies that broadly target coronaviruses
|
WO2025024265A1
(en)
|
2023-07-21 |
2025-01-30 |
Bristol-Myers Squibb Company |
Methods of assessing citrullination and activity of pad4 modulators
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
WO2025032070A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Anti-a-beta protein antibodies, methods and uses thereof
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
US20250051434A1
(en)
|
2023-08-11 |
2025-02-13 |
Merck Sharp & Dohme Llc |
Monovalent interleukin 12 (il-12) heterodimeric fc proteins
|
WO2025038492A1
(en)
|
2023-08-11 |
2025-02-20 |
Abalytics Oncology, Inc. |
Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
|
WO2025045251A2
(en)
|
2023-09-03 |
2025-03-06 |
Kira Pharmaceuticals (Us) Llc |
Multispecific constructs comprising anti-factor d moiety
|
WO2025064539A1
(en)
|
2023-09-19 |
2025-03-27 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Herv-e antibodies and methods of their use
|
WO2025072888A2
(en)
|
2023-09-28 |
2025-04-03 |
Novavax, Inc. |
Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
|
WO2025068957A1
(en)
|
2023-09-29 |
2025-04-03 |
Novartis Ag |
Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
WO2025088496A1
(en)
|
2023-10-24 |
2025-05-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
WO2025099280A1
(en)
|
2023-11-08 |
2025-05-15 |
Oxion Biologics Ab |
Improved anti-ox40l antibodies
|
WO2025106427A1
(en)
|
2023-11-14 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2025111402A1
(en)
|
2023-11-21 |
2025-05-30 |
Board Of Regents Of The University Of Nebraska |
Anti-amyloid beta antibodies and related compositions and methods thereof
|
WO2025117384A1
(en)
|
2023-12-01 |
2025-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
|
WO2025120513A1
(en)
|
2023-12-05 |
2025-06-12 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
WO2025126157A1
(en)
|
2023-12-15 |
2025-06-19 |
Advesya |
Anti-il-1rap binding domains and antibody-drug conjugates thereof
|
WO2025137523A2
(en)
|
2023-12-20 |
2025-06-26 |
Apogee Therapeutics, Inc. |
Pharmaceutical formulations of antibodies that bind interleukin 13
|
WO2025137410A1
(en)
|
2023-12-20 |
2025-06-26 |
Apogee Therapeutics, Inc. |
Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
|
US20250230251A1
(en)
|
2023-12-20 |
2025-07-17 |
Bristol-Myers Squibb Company |
Antibodies targeting il-18 receptor beta (il-18rb) and related methods
|
WO2025137284A2
(en)
|
2023-12-21 |
2025-06-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
US20250222125A1
(en)
|
2024-01-05 |
2025-07-10 |
Beigene, Ltd. |
Anti-FGFR2b Antibodies, Conjugates and Methods of Use
|
WO2025155877A2
(en)
|
2024-01-18 |
2025-07-24 |
The Regents Of The University Of California |
Antibodies binding to pad4 and uses thereof
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
WO2025179281A1
(en)
|
2024-02-23 |
2025-08-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of cardiovascular disease with antxr1 antibodies
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
WO2025184416A1
(en)
|
2024-02-27 |
2025-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single-domain antibodies and bispecific antibodies against hiv-1 and their use
|
US20250269052A1
(en)
|
2024-02-27 |
2025-08-28 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|